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1 INTRODUCTION 
 
The present thesis was funded by the FWF-Austrian Science Fund and part of 
the project “The physiological relevance of bile pigments. In vitro to in vivo 
evidence of antioxidant, anti-mutagenic and anti-carcinogenic potential and their 
mechanisms of action.” The project was performed at the Department of 
Nutritional Sciences that belongs to the University of Vienna. Data were 
collected together with Maria Theresia Gräfin zu Pappenheim, therefore 
similarities to her thesis can be observed. 
 
Bile pigments are coloring tetrapyrrols which are derived from the liver within 
the heme catabolism. These components mainly include bilirubin and biliverdin 
and were thought to be toxic or useless for a long time. However, especially the 
unconjugated form of bilirubin has come to researchers focus, as it has been 
reported to have antioxidant properties. Several in vitro and in vivo studies have 
been performed until today, investigating these functions. Certain conditions in 
humans cause moderately elevated unconjugated bilirubin concentrations, 
namely Gilbert’s syndrome. While high concentrations of bilirubin are regarded 
as harmful and toxic, conditions like in Gilbert’s syndrome have been suggested 
to be even benign. 
 
Oxidative stress, an imbalance between oxidants and antioxidants, can cause 
increased DNA damage, which is a risk factor for cancer and cardiovascular 
diseases. The cytokinesis-block micronucleus assay is a reliable method for 
measuring DNA damage in forms of micronuclei, nucleoplasmic bridges and 
nuclear buds. It has been shown that these DNA damage markers can predict 
the risk of cancer.  
 
Consequently, the present study was combining these two facts and aimed to 
investigate the antioxidant activities of bilirubin in humans and their cancer 
protective effects. The aim of this thesis was, whether unconjugated bilirubin 
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can protect the DNA, and further prevent cancer. Moreover, it was examined to 
evaluate, if antioxidants had a protective effect on DNA stability.  
 
For this purpose, individuals with Gilbert’s syndrome and matched healthy 
controls were recruited and their bilirubin concentrations, as well as their DNA 
damage were analyzed.  
 
Summarizing, the hypothesis was whether people with Gilbert’s syndrome have 
lower DNA damage than controls. 
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2 LITERATURE REVIEW 
 
2.1 Bilirubin 
Bile or gall is a yellowish-green-brown fluid, produced by the liver and stored in 
the gallbladder and it helps the body to digest fats. Bilirubin, a bile pigment, is 
the end product of a physiologic catabolism, occurring only in mammals. In 
humans, bilirubin appears mainly in the unconjugated form, where bilirubin is 
not bound to glucuronic acid. To be transported in the body, it is bound to 
albumin because of its fatsolubility. Bilirubin is unstable, sensitive to oxygen and 
light and it has been shown to have antioxidant properties [Heirwegh et al., 
1989]. 
 
2.1.1 Bilirubin chemistry 
2.1.1.1 Structure 
Bilirubin and biliverdin are colored compounds that belong to a group named 
bile pigments. These molecules have porphyrine structure, which is composed 
of four open-chain pyrrolic rings. Bile pigments share the same skeleton but 
have different ß-substituents, making them specific. Unconjugated bilirubin 
(UCB) occurs naturally as the IXα-isomer; in 4Z,15Z form. Bilirubin IXα is 
formed by cleavage of protoporphyrin-IX (heme) at the α-meso-bridge by the 
enzyme heme oxygenase (HO). Bilirubin has two further isomers, IIIα and XIIIα, 
which are not detectable in humans [Heirwegh et al., 1989; Vitek & Ostrow, 
2009]. 
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Figure 1. Structure of bilirubin IXα 4Z, 15Z in planar representation and true “ridge-tile” 
conformation [Vitek & Ostrow, 2009]. 
 
2.1.1.2 Solubility 
Unconjugated bilirubin is an apolar or lipophilic substance, which is barely 
soluble in water at physiological pH. However, the presence of two carboxyl 
groups would indicate water-solubility, but it was shown that these groups are 
not available for ionization. Bilirubin is almost impossible to dissolve in apolar 
solvents (e.g. n-hexane, methanol), but in solvents with higher polarity (e.g. 
chloroform, dichloromethane) its solubility is increasing. Bilirubin dissolves best 
in dimethyl sulfoxide (DMSO). In body fluids, unconjugated bilirubin is bound to 
proteins, giving it solubility and making it transportable. In plasma, it is bound to 
albumin, which has one high affinity binding site for bilirubin. In the cytoplasm, 
bilirubin is bound to ligandin [Blanckaert, 1981; Brodersen, 1979]. 
 
2.1.1.3 Stability and other chemical characteristics 
Unconjugated bilirubin is unstable because of the double bonds in the vinyl and 
methene groups, which can be oxidised easily. On the other side, this ability 
makes bilirubin a natural antioxidant. Bilirubin is very sensitive to oxygen and 
light, as well as to high and low pH values [Vitek & Ostrow, 2009]. 
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2.1.1.4 Measurements of bilirubin 
Bilirubin is due to the characteristics mentioned above, plus its high affinity for 
proteins and usually very low concentrations, not easy to determine in tissues 
and biological fluids. Therefore, many researchers have worked with Gunn rats, 
a mutant rat with a severe unconjugated hyperbilirubinemia. As bilirubin can be 
indicative for the diagnosis of different liver diseases, its determination is within 
clinical interest and several methods have been established (e.g. radioassay, 
ELISA or immuno-histochemical determination). The simplest determination, 
though, is the measurement of its absorption via direct absorptiometry (diazo-
method). As this method is quite simple and uncomplicated, it is frequently used 
in hospitals and measured with big analysers, e.g. Vitros. However, this 
determination is not very sensitive and can only detect high unconjugated 
bilirubin levels. Thin-layer chromatography was long used for the determination 
of conjugated bilirubin. At the moment, high-performance liquid chromatography 
(HPLC) is the preferred method. HPLC determination is highly sensitive and 
excludes oxygen and light. This analysis is able to detect different bile 
compounds as well as the bilirubin isomers IIIα, IXα and XIIIα. [Heirwegh et al., 
1989; Williams et al., 2006; Zelenka et al., 2008]. 
Consequently, HPLC was the method of choice in the present thesis project. 
 
2.1.2 Bilirubin metabolism 
Bilirubin is formed when hemoglobin is degraded, in a process called heme 
catabolism. Hemoglobin cracks into heme and globin, heme is further reduced 
to biliverdin and then to bilirubin. This degradation takes mainly place in the 
spleen. Bilirubin, which has been reported to be a powerful antioxidant, can also 
be a potentially toxic compound. Physiologic normal concentrations range up to 
17 µmol/L, however, they can be higher and cause certain diseases. This 
means that the physiological effect is depending on bilirubin concentrations. 
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2.1.2.1 Heme catabolism 
Bilirubin concentrations are related to heme degradation, as bilirubin is the end 
product of the heme catabolism. Heme is the main source, but also 
hemoproteins such as hemoglobin, myoglobin, cytochromes and hemoprotein 
enzymes are included in the pathway. The daily production of bilirubin in 
humans is approximately 300 mg. Conjugated bilirubin is also called direct 
bilirubin and unconjugated bilirubin is referred to as indirect. In the total serum, 
both forms are present, although unconjugated bilirubin is the dominant one in 
healthy humans [Blanckaert, 1981; Vitek & Schwertner, 2007; Williams et al., 
2006]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Conversion by heme oxygenase of hemoglobin to biliverdin, CO and Fe2+, with 
subsequent conversion of biliverdin to unconjugated bilirubin IXα by biliverdin reductase. Shown 
below are the constitutional IIIα and XIIIα isomers of bilirubin formed by dipyrrole exchange 
[Vitek & Ostrow, 2009]. 
 
The metabolism starts with the breakdown of senescent red blood cells into 
hemoglobin, occurring mainly in the spleen, but also in the liver and in the bone 
marrow (reticuloendothelial system). 75% to 80% of the unconjugated bilirubin 
production arise from hemoglobin, 20% to 25% from non-hemoglobin heme 
proteins in the liver, immature or defectively formed red cells in the spleen and 
heme formed in excess of globin in the bone marrow. 
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Hemoglobin is broken down to heme and globin, and heme is further degraded 
to biliverdin IXα by the enzyme heme oxygenase, which is the rate-limiting step 
in this process. Heme oxygenase catalyzes the heme ring by oxidative cleavage 
of the α-methenyl bridge between two pyrrole rings. At this step, carbon 
monoxide (CO) and one iron atom are also produced. There are two isoforms of 
heme oxygenase: HO-1 and HO-2. While HO-1 can be induced by stimuli 
causing oxidative stress (e.g. free oxygen radicals, heavy metals, bacterial 
lipopolysaccharides, hydrogen peroxide and ultraviolet light), HO-2 can not be 
induced.  
The enzyme biliverdin reductase reduces biliverdin to bilirubin and is NADPH 
dependent. Biliverdin reductase has a stereochemical preference for bilirubin 
IXα and is abundant in tissues with high heme oxygenase activity. 
Autophosphorylation of biliverdin reductase causes higher reductase activity, 
which increases bilirubin production. The consequence is an increased defense 
against oxidative stress [Stocker, 2004; Vitek & Ostrow, 2009; Vitek & 
Schwertner, 2007]. 
 
The pathway of the heme catabolism can even be noticed in the color change of 
bruises: while heme shows red or purple color, biliverdin is blue-green and 
bilirubin yellow [Schmid & McDonagh, 1975]. 
 
Mammals, only, degrade biliverdin to bilirubin. In birds, amphibians and reptiles 
the heme catabolism stops at biliverdin and it is directly excreted. The 
conversion from the non-toxic biliverdin to the potentially toxic bilirubin, which is 
additionally expensive in energetic costs remains still an unanswered question. 
One explanation, though, might be the beneficial role of bilirubin as an 
antioxidant [Stocker et al., 1987]. 
 
2.1.2.2 Transportation and excretion 
To provide transportation in the blood circulation, unconjugated bilirubin is 
strongly bound to albumin. This protein shows high binding affinity and is 
abundantly available. As a consequence, unbound bilirubin is hardly present 
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(less than 0.1%). As cytotoxicity is referred to the concentration of unbound 
bilirubin, it seems, albumin is not only responsible for bilirubin transportation, 
but also has a detoxification function. Bound to albumin, bilirubin reaches the 
liver for hepatic uptake. In the hepatocytes bilirubin becomes water-soluble by 
conjugation with glucuronic acid, glucose or xylose by the enzyme UDP-
glucuronosyl-transferase. These mono- and diconjugates are then excreted in 
the bile. In the intestine, conjugated bilirubin is further hydrolysed by ß-
glucuronidases and anaerobic bacteria into urobilinogens and urobilins, which 
are reabsorbed by the enterohepatic circulation and are excreted by the kidney. 
Urobilins that remain in the intestine are oxidized to stercobilins and excreted in 
the feces [Blanckaert, 1981; Stocker, 2004; Vitek & Ostrow, 2009]. 
 
2.1.2.3 Pathophysiology 
High serum bilirubin concentrations can induce very dangerous conditions, 
caused by its toxicity. On the other side, some conditions of elevated bilirubin 
are benign and do not require any clinical treatment.  
 
Normal unconjugated serum bilirubin concentrations range up to 17 µmol/L 
(1 mg/dL). Concentrations above 30 µmol/L (1.8 mg/dL) are assumed to cause 
health risks, especially neurological dysfunctions due to toxic bilirubin 
concentrations in the brain. These high concentrations cause yellow 
discoloration in sclera and skin and are diagnosed as jaundice (icterus). 
[Silbernagl & Despopoulos, 2003; Stocker, 2004]. 
 
An icterus can be classified as prehepatic, intrahepatic and posthepatic. 
The prehepatic icterus occurs when hemolysis, and as a consequence 
bilirubin production, is increased. A defect liver can cause an intrahepatic 
icterus. Drugs, poisons or hepatitis can induce this defect. The posthepatic 
icterus arises after blockage of the bile duct, which can be caused by gall 
stones or tumors. 
Newborns usually develop a hyperbilirubinemia, a physiological jaundice, which 
is a consequence of the destruction of fetal hemoglobin. If this hemolysis is 
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increasing, a pathological neonatal jaundice occurs. Untreated, bilirubin 
concentrations rise and can harm the brain. One kind of treatment is 
phototherapy, where the newborn is irradiated with light at a wavelength of 400 
to 500 nm, making unglucuronated bilirubin water-soluble. Another one is 
replacement-transfusion [Löffler, 2008; Silbernagl & Despopoulos, 2003]. 
 
These forms are referred to as acquired hyperbilirubinemias. Inherited 
syndromes are Gilbert’s, Crigler-Najjar, Dubin-Johnson and Rotor. 
 
Gilbert’s syndrome 
The Gilbert’s syndrome is a relatively frequent benign polymorphism, with mildly 
elevated serum unconjugated bilirubin concentrations (>17.1 µmol/L). It affects 
3 to 17% of the general population, with a greater percentage in men than in 
women (12.4% and 4.8%). Moreover, mean bilirubin concentrations are 
significantly higher in males, caused by androgen steroid inhibition of bilirubin 
enzymatic glucuronidation [Bulmer et al., 2008b; Radu & Atsmon, 2001]. 
Gilbert’s syndrome is a rather harmless condition, which does not cause chronic 
liver inflammation, histological changes or progressive fibrosis. People with 
Gilbert’s syndrome have a ~30% lower hepatic activity of uridine diphosphate 
glucuronosyltransferase (UGT1A1) than normally, caused by a mutation in the 
gene promoter. This polymorphism (UGT1A1*28) shows additional TAs in the 
TATAA box. However, other factors can lead to increased bilirubin levels such 
as psychological stress, infection, fasting and physical activity or hemolytic 
disease [Bosma, 2003; Bulmer et al., 2008b; Danoff et al., 2004; Strassburg, 
2010]. 
 
Crigler-Najjar syndrome 
The Crigler-Najjar syndrome is a more severe form, which can cause death if 
left untreated. This syndrome is another mutation of the UGT1A gene with 
(almost) no glucuronidation activity. Two types are described, of which type 1 
has no enzyme activity at all and type 2 has an activity below 30% [Strassburg, 
2010]. 
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Dubin-Johnson syndrome and Rotor-syndrome 
These syndromes are rare but benign abnormalities of the hepatobiliary 
transport in which direct and indirect bilirubin can be elevated. Both forms 
require no therapy [Strassburg, 2010]. 
 
While highly enhanced bilirubin concentrations can cause severe neurological 
defects or even death, mildly elevated concentrations (like in Gilbert’s 
syndrome) are assumed to be beneficial, due to the antioxidant properties of 
unconjugated bilirubin. 
 
2.1.3 Physiologic relevance of bilirubin 
The physiologic capacity of bilirubin may be its beneficial effects as an 
antioxidant. It was shown that bilirubin is a potent antioxidant and can act 
against free radicals. Free radicals can cause biological damage, referring to as 
oxidative stress. Oxidative DNA damage is linked to the development of cancer. 
Consequently, if bilirubin can reduce this damage, it may be protective against 
cancer. 
 
2.1.3.1 Oxidative stress and reactive oxygen species generation 
Oxygen is essential for humans, however, in the oxidative metabolism, O2 can 
create toxic substances; namely reactive oxygen species (ROS). ROS are 
strong oxidants or very reactive free radicals that can be either harmful or 
beneficial. Their positive effects occur at low or moderate concentrations and 
include cellular and mitogenic responses. Harmful consequences are biological 
damages by free radicals, which can lead to oxidative stress. If molecular 
oxygen takes an additional electron, the superoxide anion radical (•O2−) is 
formed. Another reduction forms peroxide anion (O22−), which can form 
hydrogen peroxide (H2O2). Adding a third electron arises in the production of the 
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very dangerous hydroxyl radical (•OH), which is highly reactive [Valko et al., 
2007; Kryston et al., 2011; Koolman & Röhm, 2003]. 
 
Oxidative stress is an imbalance between oxidants and antioxidants [Sies, 
1997]. It is the result of an overproduction of ROS and a deficiency of 
antioxidants. ROS can harm cell structures, nucleic acids, lipids and proteins, 
and especially the hydroxyl radical reacts with the DNA and affects DNA 
synthesis and repair. This oxidative damage, causing harmful influence on 
genetic material is assumed to be the first step in mutagenesis, carcinogenesis 
and aging, and is consequently involved in the development of numerous 
diseases, including cancer, diabetes mellitus, inflammatory diseases and 
neurodegenerative disorders [Kryston et al., 2011; Valko et al., 2007]. 
Mutations in DNA can lead to the development of cancer. Elevated DNA 
damages, arising from oxidative damage, were investigated in cancer. 
Additionally, in case of a tumor growth, high oxidative stress status was 
measured [Cooke et al., 2003; Kryston et al., 2011]. 
 
2.1.3.2 Antioxidants 
Halliwell (2007) defined antioxidants as “any substance that delays, prevents or 
removes oxidative damage to a target molecule”. 
Generally, antioxidants should minimize the exposure to O2 [Halliwell, 2007]. 
Antioxidants react easily with oxidizing substances and protect cells from 
oxidation, respectively ROS and free radicals. According to Valko et al. (2006), 
an antioxidant should scavenge free radicals; chelate redox metals; act 
synergistically with other antioxidants; activates gene expression; be absorbed 
easily; have a physiologically appropriate concentration in tissues and body 
fluids and function in both hydrophilic and/or membrane areas. 
 
There are two kinds of antioxidants: enzymatic and non-enzymatic. Superoxide 
dismutase, glutathione peroxidase and catalase belong to the enzymatic 
antioxidants. Vitamin C (ascorbic acid), vitamin E (α-tocopherol), glutathione, 
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carotenoids, flavonoids as well as bilirubin are non-enzymatic antioxidants 
[Koolman & Röhm, 2003; Valko et al., 2006]. 
 
2.1.3.3 Antioxidant activities of bilirubin 
Although traditional chinese medicine is known to have already used bilirubin 
salts for healing and cure, it was still believed for a long time that bilirubin is 
either useless or just a toxic compound, especially at high concentrations. In the 
1950’s though, bilirubin was discovered to have antioxidant properties, by 
inhibiting oxidation from vitamin A and linoleic acid in the intestinal tract [Rao et 
al., 2006; Stocker et al., 1987]. Stocker indicated in 1987 that bilirubin might be 
of physiological importance. Since then, several studies confirmed the 
antioxidant potential of bilirubin (and biliverdin) [Frei et al., 1988; Neuzil & 
Stocker, 1994; Stocker & Peterhans, 1989; Vitek & Ostrow, 2009]. It was further 
reported that bile pigments have anti-complement, anti-inflammatory, anti-viral, 
anti-apoptotic and anti-mutagenic effects [Bulmer et al., 2008a]. 
 
The antioxidant activity of bilirubin arises from its chemical structure. All forms, 
free, albumin-bound and conjugated bilirubin, have a system of conjugated 
double bonds and a pair of reactive hydrogen atoms. Especially these reactive 
atoms make it an antioxidant through H-donation to radicals. This capability 
results in reduction of oxidation of low density lipoproteins (LDL) and other 
lipids, which explains its anti-inflammatory properties [Schwertner & Vitek, 2008; 
Stocker, 2004]. 
 
Another aspect is the similar antioxidant activity of bilirubin to ascorbate. While 
most antioxidants affect only 1e-oxidants, but are poor scavengers for 2e-
oxidants, bilirubin and ascorbate are effective against both kinds. Singlet 
oxygen, hypochlorus acid, quinones and peroxynitrite are examples for 2e-
oxidants, scavenged by bilirubin [Stocker, 2004]. 
 
As mentioned earlier, heme oxygenase is the enzyme which reduces heme to 
biliverdin in the heme catabolism. Heme oxygenases are protective enzymes, of 
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which two isoforms exist: HO-1 and HO-2. HO-1 is derived from the heat-shock 
protein 32 and induced by oxidative stress, heavy metals, hydrogen peroxide 
and other factors, while HO-2 is constitutive. Furthermore, HO-1 is important for 
the antioxidant defense system. The degradation of heme by HO-1 not only 
results in the antioxidant bilirubin, but also produces iron and carbon monoxide. 
Iron further generates ferritin, which is beneficial for the endothelium. Carbon 
monoxide functions as a vasodilator, a second messenger and neurotransmitter 
in the brain. Several studies reported the positive effects of heme oxygenase, 
e.g. decreasing ROS production, ischemic liver protection, heart, renal and 
intestinal ischemia and reperfusion, as well as minimizing atherosclerotic 
lesions [Jansen et al., 2010; Vitek & Schwertner, 2007]. Besides, heme 
oxygenase was suggested to have also pro-oxidant effects [Ryter & Tyrrell, 
2000]. 
 
2.1.3.4 The theory of a redox cycle of bilirubin and biliverdin 
Although the antioxidant properties of bilirubin seem clear, it is yet not 
completely solved how it protects cells from oxidation - apart from structural 
aspects. Lately, the theory of a redox cycle of bilirubin and biliverdin was 
discussed. In this cycle, bilirubin is oxidized to biliverdin and then reduced back 
to bilirubin by the ubiquitous biliverdin reductase. This assumption was based 
on a report by Doré et al. from 1999, which showed that even nanomolar 
concentrations of bilirubin protected cells from H2O2 toxicity in vitro. The cycle-
theory suggested that bilirubin molecules act again and again and therefore 
could explain high effectiveness even at low concentrations. 
The redox cycle was investigated by Maghzal et al. (2009) under various 
conditions and these results could not show that bilirubin generates biliverdin, 
nor that biliverdin reductase is an important protector of cells. Yet, there was 
suspect of an anti-apoptotic bilirubin function. McDonagh (2010) studied the 
redox cycle as well, but couldn’t find proof to it either. Moreover, McDonagh 
termed this theory as highly doubtful. Data misinterpretation and impure bilirubin 
may have caused a false assumption. 
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2.1.3.5 Measurements in vitro 
Antioxidant properties were examined by Stocker et al. (1987) in a lipid in vitro 
system. Linoleic acid was oxidized by a free radical chain and formed linoleic 
acid hydroperoxide (LOOH), which can be measured. Bilirubin and biliverdin at 
very low concentrations reduced the formation of LOOH significantly. 
Furthermore, bilirubin inhibited partially the chain reaction. These results 
suggest that bilirubin can scavenge peroxyl radicals. For physiological 
relevance, bilirubin was then compared with ß-carotene and α-tocopherol. 
Bilirubin showed similar rates of antioxidant activity and at low oxygen 
concentrations bilirubin could even beat α-tocopherol. 
As already mentioned above, most circulating bilirubin in humans is bound to 
albumin and results in increased specificity and reactivity. Albumin-bound 
bilirubin inhibits oxidative damage of fatty acids, which are transported on 
albumin. Moreover, it protects proteins from ROS caused damage and at 
normal concentrations albumin-bound bilirubin is an efficient radical scavenger 
in humans that protects lipids as well as proteins [Stocker, 2004]. 
 
Two studies showed in vitro evidence for an anti-cancer effect of bilirubin. 
Keshavan et al. (2004) showed that bilirubin had a reducing effect on the 
viability of colon adenocarcinoma cell lines at physiologic concentrations (0-
50 µM) and also stimulated apoptosis in HCT15 colon adenocarcinoma cells. 
These observations were only seen with the unconjugated form of bilirubin. Rao 
et al. (2006) investigated the effect of bilirubin on human carcinoma cell lines. 
Cells were prepared, treated with physiological bilirubin concentrations 
(10 µg/mL) and incubated. In hepato-carcinoma cells an anti-oxidative effect 
was noticed and, surprisingly, in TMK-1 cell lines a pro-oxidant effect. Other 
antioxidants had no effect on TMK-1 cell lines. These results lead to the 
assumption that bilirubin has an anti-cancer activity. 
 
Bulmer et al. (2007) studied on the anti-mutagenic properties of bile pigments. 
Unconjugated bilirubin, bilirubin ditaurate and unconjugated biliverdin were 
tested using the Ames Salmonella test. Bilirubin as well as biliverdin showed 
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anti-mutagenic activity and were able to inhibit genotoxic effects of several 
mutagens. Moreover, antioxidative activity was tested and found positive in 
bilirubin and biliverdin. 
 
While the antioxidant activity of bilirubin seems to be proven in in vitro systems, 
its properties are not so clear in vivo. Although assumed to be antioxidative in 
vivo as well, there is only indirect evidence. To get more information, the effect 
of altered pigment concentrations on established in vivo markers, e.g. oxidized 
lipids, should be investigated [Stocker, 2004]. One report that indicates 
antioxidant bilirubin function in vivo though, was published by Dennery et al. 
(1995). They investigated oxidative stress in Gunn rats and nonjaundiced 
control rats after exposure to oxygen. Thiobarbituric acid and lipid 
hydroperoxides were reduced in Gunn rats and therefore support the 
antioxidative theory. 
 
2.1.4 Epidemiological studies 
Antioxidant activity and beneficial effects of bilirubin have been in focus of 
researchers for many years. In the following section epidemiological studies 
showing evidence to these properties are presented. 
 
2.1.4.1 Cardiovascular disease 
One of the first reports that showed an association of bilirubin and coronary 
artery disease (CAD) was published in 1994 by Schwertner et al. 619 male 
American pilots and navigators were examined and an inverse relation between 
low total serum bilirubin and an increased risk of CAD was found. This relation 
was statistically significant and as strong as the association with smoking or 
systolic blood pressure. Although bilirubin was assumed to be an antioxidant, 
yet it was not known that bilirubin could prevent or protect from CAD. 
This inverse relationship between total bilirubin and CAD prevalence was 
shown again recently. In a study, including 100 healthy and 100 subjects 
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diagnosed with CAD, it was reported that bilirubin was decreased in CAD 
patients compared to controls. In other words, subjects with low serum bilirubin 
concentrations had a higher risk for CAD [Ghem et al., 2010]. 
 
A connection between serum bilirubin and cardiovascular disease (CVD) was 
found in an association study of the Framingham Heart Study. The Framingham 
Heart Study started in 1948, investigating on the risk factors of CVD in the 
general population. Among these, 1780 subjects with an average age of 36 
years were analysed retrospectively, as these subjects had given genotype 
information for UGT1A1 polymorphism. A significantly reduced risk for CVD and 
coronary heart disease was noticed in subjects with UGT1A1*28, which causes 
mildly elevated serum bilirubin levels [Lin et al., 2006]. 
 
Another study investigated effects of bilirubin on individuals with Gilbert’s 
syndrome. 50 people with this hyperbilirubinemia were compared to a control 
group and the prevalence for ischemic heart disease was 2% in relation to 
12.1%. It was suggested that unconjugated bilirubin may prevent ischemic heart 
disease development [Vitek et al., 2002]. 
 
In a study by Bulmer et al. (2008b) nine individuals with Gilbert’s syndrome 
were compared to 12 controls. The aim was to find mechanisms that are 
responsible for the protection from CVD at high bilirubin concentrations. 
Gilbert’s syndrome was identified by circulating unconjugated bilirubin levels 
>17.1 µmol/L (1 mg/dL). However, this study found no differences within the 
groups in their antioxidant status and oxidative stress, but a significantly 
reduced susceptibility of serum to oxidation was noticed in Gilbert’s syndrome 
patients. 
 
Yesilova et al. (2008) investigated if high serum bilirubin concentrations can 
protect LDL from oxidation. Therefore, 17 patients diagnosed with Gilbert’s 
syndrome and 15 matched, healthy controls were compared. There were no 
significant differences between the groups. However, LDL oxidation 
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susceptibility experiments showed a longer lag phase in Gilbert’s syndrome 
patients compared to controls. Also, serum bilirubin concentrations and LDL 
oxidation susceptibility values were significantly correlated. These findings 
might indicate that elevated bilirubin levels are related with low LDL oxidation, 
and this is suggested to protect from coronary heart disease. 
 
In a study by Tapan et al. (2011) 42 male persons with Gilbert’s syndrome were 
compared to 52 matched healthy controls. Small dense LDL cholesterol, 
oxidized LDL and high-sensitivity C-reactive protein levels were examined and 
all three values were lower in the Gilbert’s syndrome group than in controls. 
Oxidized LDL is involved in the development of atherosclerosis, consequently it 
was assumed that elevated bilirubin might decrease the risk of this condition.  
 
2.1.4.2 Cancer 
In the population from the Belgium Inter-university Research on Nutrition and 
Health (BIRNH) study, Temme et al. (2001) investigated on 5460 men and 4843 
women, aged between 25 and 74 years, the association between serum 
bilirubin and cardiovascular and cancer mortality. Originally, the BIRNH study 
investigated the relationship between diet and mortality and was performed 
from 1981 to 1984. Ten years after the first data collection, vital status and 
cause of death of participants were ascertained. Average serum bilirubin 
concentrations in men were 0.44 mg/dl (range: 0.1–3.8 mg/dl) and 0.35 mg/dl 
(range: 0.1–2.8 mg/dl) in women. Results showed that men with higher serum 
bilirubin concentrations had a 58% lower risk of cancer mortality. Women 
showed same trends (24% lower risk), but no statistic significance. 
 
A similar evaluation was done by Zucker et al. (2004) in the United States of 
America. The Third National Health and Nutrition Examination Survey 
(NHANES III) is a huge database performed between 1988 and 1994 including 
40 000 people. Among these, 16 865 subjects had given serum bilirubin data, 
with significantly lower concentrations in women (0.52 ± 0.003 mg/dL) 
compared to men (0.72 ± 0.004 mg/dL). A significant inverse relationship 
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between serum bilirubin concentrations and colorectal cancer was investigated. 
An increase of each 1 mg/dL total bilirubin caused a decrease in cancer risk. As 
the NHANES III database did not differ between conjugated and unconjugated 
bilirubin it can not be sure that the effect originates from the unconjugated form, 
however, the study authors suspected so. These investigations indicate that 
bilirubin protects from cancer. 
 
Horsfall et al. (2011) published a report comparable to the above ones recently. 
Information was gained from The Health Improvement Network (THIN) 
database from the United Kingdom, including more than 7 million people. 
504 206 individuals were included with a median follow-up of 8 years. Average 
serum bilirubin concentrations in men were 0.64 mg/dl (interquartile range: 
0.47–0.88 mg/dl) and 0.53 mg/dl (interquartile range: 0.41–0.70 mg/dl) in 
women. It was shown that higher concentrations of bilirubin decreased the risk 
of lung cancer and all-cause mortality. These findings were similar both in men 
and women. 
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2.2 Oxidative DNA damage 
 
2.2.1 DNA & DNA damage 
 
2.2.1.1 DNA 
Deoxyribonucleic acid (DNA) is a polymer molecule, made of nucleotides. DNA 
contains and storages the genetic information of all living cells. Therefore, 
changes (mutations) in the DNA sequence can lead to damage in the molecule. 
While on one side mutations are important for biological evolution, on the other 
side too much can be harmful. Mutations are caused by physical and chemical 
influences or by random errors of DNA replication or recombination [Koolman & 
Röhm, 2003].  
 
2.2.1.2 Mitosis and cell cycle 
 
Figure 3. The cell cycle [David Darling, 2011]. 
 
Every eukaryotic cell has to go through mitosis and the cell cycle. Mitosis is the 
process of cell division. The cell cycle can be divided into four phases: G1, S, G2 
and M. The G0 phase is a resting phase, in which cells can endure for a long 
time. After the last mitosis, proliferating cells enter the G1 phase, where the cell 
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is growing and synthesizing its materials. The next phase is the S phase, which 
is entered by the influence of growing factors. In this phase, DNA replication 
takes place and in the end the cell is tetraploid. After that, cells enter the G2 
phase, which is relatively short. Finally, cells enter the M phase. Mitosis has 
four stages: prophase, metaphase, anaphase and telophase. The division of the 
cytoplasm, resulting in two daughter cells with genetic identical material is 
termed cytokinesis. At prophase the nuclear envelope disintegrates, the 
nucleolus disappears and the centrioles, when present, duplicate and migrate to 
opposite poles of the cell. At metaphase the chromosomes line up in the middle 
of the cell, called the metaphase plate. This alignment of the chromosomes 
marks the end of the metaphase. At anaphase chromatids separate and are 
pulled to opposite poles of the cell. At telophase the chromosomes uncoil and 
begin to carry out their physiological functions. A nuclear envelope re-forms 
about each set of chromosomes, nucleoli form and cytokinesis takes place. 
Now the cells enter the G1 phase of the cell cycle and the process can start 
again. 
The cycle needs to be strictly controlled. If cells enter a phase without 
completing the previous one, cell death is likely. Cyclins and cyclin-dependent 
kinases (CDKs) control the cell cycle phases. To prevent that DNA damaged 
cells enter the cycle the tumor suppressor proteins p53 and retinoblastom 
protein work together with cyclin-dependent kinases [Löffler, 2008; Tamarin, 
1993]. 
 
2.2.1.3 DNA damage 
DNA damage arises from several mutagens, free radicals and reactive oxygen. 
There are different kinds of DNA damage and in the best case they get repaired 
or eliminated. 
DNA damage depends on the type of mutagen and on where it reacts. 
Mutagens can react with DNA directly (e.g. ionizing radiation, oxidizing 
chemicals, UVA solar light) or indirectly (e.g. hydroxyl radical) via protein 
binding and formation of free radicals. Free radicals are produced when a 
cellular imbalance occurs, and oxygen is available. This can result in reactive 
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oxygen species. Different types of DNA damage can occur as single-strand 
breaks and double-strand breaks, DNA adducts or gene-, chromosome- and 
genome mutations [Mateuca et al., 2006; Kryston et al., 2011]. 
 
2.2.2 Measuring DNA damage 
Although there are mechanisms to prevent DNA damage, it still can occur. 
These damages can be detected with specific methods, e.g. the chromosome 
aberration assay and the micronucleus assay. Today, the micronucleus assay is 
frequently used and can detect different kinds of DNA damages. These 
damages are measured in lymphocytes and occur as micronuclei, 
nucleoplasmic bridges and nuclear buds. 
 
2.2.2.1 The chromosome aberration assay 
The chromosome aberration assay in peripheral blood lymphocytes (PBL) has 
been used in the past 30 years to measure genotoxic carcinogens. Several 
studies showed an association between chromosomal aberrations and an 
increased risk of cancer. However, this method is in disadvantage compared to 
the nowadays more frequently used micronucleus assay [Mateuca et al., 2006; 
Bonassi et al., 2008]. 
 
Chromosomal aberrations are either changes in the chromosome structure or 
in the chromosome number. 
Structural changes are generated by DNA breakage, replication, 
synthesis inhibition and other mechanisms. They can be differed in 
chromosome-type aberrations and chromatid-type aberrations. Chromosome-
type aberrations occur from incompletely repaired or unrepaired double strand 
breaks and chromatid-type aberrations from base modifications or single strand 
breaks. These aberrations are then repaired, incorrect repaired or not repaired 
at all. On microscope slides the incorrect repair as well as the not repaired 
damages can be observed. 
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Numerical changes represent modifications in the normal chromosome 
number, termed aneuploidy or polyploidy [Mateuca et al., 2006]. 
 
2.2.2.2 The cytokinesis-block micronucleus assay 
The cytokinesis-block micronucleus assay (CBMN) was developed to measure 
micronuclei. In the past years, scoring of nucleoplasmic bridges and nuclear 
buds was established and became more important. Hence, the CBMN assay 
has turned into a “cytome” concept in which every cell is scored. Besides MN, 
NPB and NBUD, apoptosis and necrosis as well as mono- bi- and 
multinucleated cells are counted. All these formations give information about 
chromosome breakage, chromosome loss, non-disjunction, cell death and 
cytostasis in human lymphocytes. The cytokinesis inhibitor cytochalasin-B, 
added 44 hours after the cultivation start, blocks cell division at the stage of 
binucleated cells, to which scoring is restricted. 
Due to its statistical power and relative simpleness, the CBMN assay has 
become a standard method for testing genetic toxicology and measuring 
chromosomal DNA damage in humans. Moreover, it has been proposed, that 
the frequency of MN can estimate the risk of cancer and cardiovascular disease 
[Fenech & Bonassi, 2011; Fenech, 2006; Mateuca et al., 2006]. 
 
Micronuclei (MN) are biomarkers for chromosome breakage (acentric 
fragments) and/or chromosome loss. They occur in once-divided binucleated 
cells and have the same morphology as the main nucleus, by the exception that 
they are smaller. 
MN from acentric chromosome or chromatid fragments can result from 
several mechanisms. Misrepair of DNA double-strand breaks can produce 
chromatid and chromosome fragments. A few fragments originate from 
unrepaired double-stranded DNA breaks. Another mechanism causing MN 
formation is simultaneous excision repair of damaged or wrong bases 
incorporated into the DNA. Especially uncompleted gap-filling can cause DNA 
double-strand breaks and consequently MN. Additionally, MN can arise from 
leftover chromosome material from nucleoplasmic bridges (see later). 
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MN can originate from whole chromosome malsegregation at anaphase. 
This is caused by chromosomes that were not included in the daughter nuclei 
during mitosis and could therefore not reach the spindle poles. One mechanism 
is hypomethylation of cytosine in centromeric and pericentromeric repeat 
sequences. Another origin might be defects in kinetochore proteins, which are 
required for the meshing of chromosomes with the spindle. Defects in mitotic 
spindle assembly, mitosis check point defects and abnormal centrosome 
amplifications are mentioned as well. More recently discussed are dicentric 
chromosomes resulting from telomere end fusions [Fenech, 2000; Fenech et 
al., 2011]. 
 
 
Figure 4. MN and NPB formation in cells undergoing nuclear division. MN originate from either 
lagging whole chromosomes or acentric chromosome fragments. NBP originate from dicentric 
chromosomes that may be caused by misrepair of double strand DNA breaks or telomere end 
fusions. These events can only be observed in cells completing nuclear division, which are 
recognized by their binucleated appearance after cytokinesis blocking with cytochalasin-B 
[Fenech, 2007]. 
 
Nucleoplasmic bridges (NPB) are a biomarker of chromosome rearrangement 
and arise when centromeres of dicentric chromosomes are pulled to opposite 
poles of the cell during anaphase. These dicentric chromosomes develop from 
misrepair of chromosome breaks and can result in a NPB. They can also 
originate when the telomere ends are merged together, caused by adverse 
arrangement of telosome protein structure. Generally, NPB would break during 
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cytokinesis, however, in the micronucleus assay they are still visible, since the 
cytokinesis inhibitor cytochalasin-B is used. This poison stops cell division at the 
binucleated stadium, where NPB are stable. 
NPB frequency is growing by exposure to endogenous oxidants, ionising 
radiation, polycyclic aromatic hydrocarbons, cigarette smoke carcinogen, 
vanadium pentoxide and deficiencies in folate and selenium [Fenech et al., 
2011]. 
 
Nuclear buds (NBUD) are a biomarker of gene amplification. They occur during 
the S phase of the cell cycle (nuclear budding) and have the same morphology 
as MN, indeed they are still connected to the nucleus. Similar to MN and NPB, 
NBUD formation show different ways of origin. They are predominantly built 
from interstitial or terminal acentric fragments. Another possibility is that NBUD 
are leftovers from DNA after nuclear division or they could also be formed by 
eliminating unnecessary chromosomes. Potentially, NBUD on one or both 
nuclei can arise after a NPB is broken [Fenech et al., 2011; Mateuca et al., 
2006]. 
 
Figure 5. The various possible fates of cultured cytokinesis-blocked cells following exposure to 
cytotoxic/genotoxic agents. Using these biomarkers within the CBMN assay, it is possible to 
measure the frequency of chromosome breakage (MN), chromosome loss (MN), chromosome 
rearrangement, for example, dicentric chromosomes (NPB), gene amplification (NBUD), 
necrosis and apoptosis. In addition, cytostatic effects are readily estimated from the ratio of 
mono-, bi- and multinucleated cells [Fenech, 2007]. 
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Apoptosis is a genetically programmed cell death leading to degradation. 
Apoptosis can be identified by its morphology including change of cell 
membrane, shrinking of the nucleus, chromatin condensation and chromosomal 
DNA fragmentation. Macrophages and other cells recognize apoptotic cells and 
remove them through phagocytosis, without causing inflammation [Koolman & 
Röhm, 2003]. 
 
In contrast, necrosis is caused by physical or chemical damages. Cells can 
swell and burst and this can lead to an inflammation. While apoptosis can be 
considered to be beneficial, necrosis refers usually to “unnatural” cell death 
[Koolman & Röhm, 2003]. 
 
2.2.3 Influencing factors for DNA damage markers 
The influences of age and gender on MN in PBL were already discovered in the 
mid-1980s and steadily approved in numerous studies until today. Nutrition also 
has a huge influence on MN formation. So far, nine micronutrients were 
identified to have an effect on genome stability in humans. Some studies 
showed a reduction of MN with moderate exercise, however, the effects of 
extreme exercise are still unclear. The relevance of smoking is yet unexplained, 
as some studies reported increased MN frequencies in smokers and others 
don’t. However, heavy smokers do have significantly elevated MN frequencies. 
High alcohol consumption is considered to have an increasing effect on MN 
formation as well [Fenech & Bonassi, 2011]. 
 
2.2.3.1 Age and gender 
MN frequencies increase with age in both males and females but generally 
females have higher values. 
In 1999, Peace and Succop analyzed 11 studies from different countries. All, 
except one of them, used the CBMN assay. 10 studies observed a positive 
correlation between age and MN frequency. Regarding the gender effect, 3 out 
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of 11 studies did not provide data, 5 proposed no differences and 3 showed 
differences with MN being greater in females.  
In 2001, Bonassi et al. evaluated data from 25 laboratories from 16 countries, 
including almost 7000 subjects (HUMN-project). They confirmed that MN 
increased with age in both genders. Women showed a 19% higher frequency in 
MN than men. 
In 2007, Wojda et al. published that both men and women had higher MN 
frequencies as they got older and higher rates were found in females. 
Similar observations can be found in several other publications [Coskun et al., 
2011; Costa et al., 2007; Garaj-Vrhovac et al., 2008; Mateuca et al., 2006]. 
 
Many factors can cause the age-increasing effect of MN. There are cumulative 
effects of gene mutations that are implied in DNA repair, chromosomal division 
and cell cycle checkpoints, or alterations of chromosomes due to the exposure 
to genotoxins, poor nutrition, stress, sickness and other factors. Generally, an 
unhealthy lifestyle is considered to cause higher MN formation. The reason for 
more MN in women might be explained by the fact that females have two X 
chromosomes (while men have one) and these tend to get lost as MN easier 
than other chromosomes. 72% of the observed MN in women can be accounted 
by the X chromosome [Fenech & Bonassi, 2011; Fenech et al., 2011]. 
 
2.2.3.2 Folic acid and vitamin B12 
Folic acid and vitamin B12 are important factors in the DNA metabolism. Folic 
acid is relevant for the synthesis of dTMP from dUMP. If there is a deficiency of 
this micronutrient, uracil is incorporated into DNA instead of thymine. This 
wrong incorporation can cause point mutation, single- and double-strand DNA 
breaks, chromosome breakage and MN. Folic acid and vitamin B12 are 
important for the synthesis of methionine and S-adenosyl methionine (SAM). 
SAM determines gene expression and DNA conformation. Vitamin B12 
deficiency causes reduced SAM synthesis, leading to uracil incorporation into 
DNA. 
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In summary, a deficiency of folic acid and vitamin B12 can lead to greater DNA 
damage and altered methylation of DNA. These are both risk factors for cancer. 
Also, deficiencies raise levels of homocysteine which is a risk factor for 
cardiovascular disease [FENECH, 2001]. 
 
In 2005, Fenech et al. examined in 190 healthy subjects the relationship 
between diet and genome damage. Five micronutrients were identified (retinol, 
vitamin E, folate, nicotinic acid and calcium) to be protective and reduce MN 
formation. Concerning folate, its importance for chromosomal stability could be 
shown and that folate deficiency caused elevated MN frequencies. 
A study from Stopper et al. (2008) investigated the effects of folate acid and 
vitamin B12 supplementation on 27 dialysis patients. They measured MN 
frequencies each three times before and after supplementation and found 
significant reductions of genome damage after the supplementation. 
Minozzo et al. (2010) investigated genotoxic damage in lead-exposed workers, 
considering folate and vitamin B12. Lead-exposed subjects showed significantly 
higher MN frequencies than the control group. The study was conducted in 
Brazil, where flour is enriched with folic acid since 2004. Therefore, B12 and 
folic acid concentrations were similar in both groups. Subjects with equal or 
higher folic acid levels than mean showed significantly more MN and NPB. 
Previous studies showed the same effect, suggesting that folate concentrations 
increase with age. Referring to the authors, these results might suggest that 
only high folate concentrations are not enough for reducing MN formation. 
Milic et al. (2010) examined folate and vitamin B12 concentrations in 36 male, 
healthy subjects for DNA damage. These findings showed that individuals with 
lowest vitamin B12 concentrations had highest MN frequencies. This leads to 
the conclusion that vitamin B12 is involved in DNA integrity. These results may 
also indicate that the positive effect of folic acid and vitamin B12 is measureable 
in undernourished persons as well as in healthy ones. 
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2.2.4 DNA damage markers as predictor of cancer risk 
Back in 1902, Theodor Boveri made a remarkable finding, when he linked 
chromosomal abnormalities with cancer. Mutation and selection are principally 
important evolutionary mechanisms, however, they can cause chromosomal 
aberrations and consequently lead to cancer development. Most tumors show a 
huge amount of chromosomal aberrations which reflect an accumulation of 
genetic damage. Consequently, genomic instability indicates the process of 
carcinogenesis. The intensity of damages can be measured and reflect the 
cancer risk. MN, NPB and NBUD are caused by chromosomal rearrangements, 
altered gene expressions or aneuploidy – effects of chromosomal instability 
which are often seen in cancer. Therefore, these biomarkers can predict the risk 
of cancer, which was already shown in several studies. There is evidence that 
cancer patients have higher frequencies of MN, NPB and NBUD [Bonassi et al., 
2011]. 
 
2.2.4.1 Micronuclei in healthy individuals and cancer patients 
A first association of chromosomal aberrations and cancer risk was made by a 
Nordic study group. They measured chromosomal aberrations, sister chromatid 
exchange or MN in PBL in 3182 subjects between 1970 and 1988. In a follow-
up period lasting until 1991 they observed 85 cancer incidents. They found a 
significant positive trend with chromosomal aberrations and cancer risk. No 
relation was found in MN frequencies and cancer risk, due to the lack of data, 
as only 11 cancer cases were examined for MN formation before their diagnosis 
[Hagmar et al., 1994]. 
In a huge analysis of 6718 subjects from 10 countries it was indicated that MN 
in PBL were a predictive biomarker of cancer risk even in a healthy population. 
Bonassi et al. (2007) compared data from 20 laboratories published between 
1980 and 2002, by splitting them into groups of low, medium and high MN 
frequencies. In a follow-up period of eight years, carcinogenesis and mortality of 
subjects were investigated. Significant increases of cancer incidences were 
found in the medium and high group, independent from nationality. Hence, both 
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groups showed a decreased cancer-free survival, compared to the low group. 
Although an association of MN and cancer was observed with different types of 
cancer, only urogenital and gastro-intestinal cancers were statistically significant 
[Bonassi et al., 2007]. 
In a similar study from Italy, published in 2008, it was aimed to analyze cancer 
in healthy individuals. Between 1991 and 1993 blood samples from 1650 
subjects were collected. A follow-up period until January 2005 was performed. 
The findings showed that 111 people died, of which 52 persons had cancer. 
Their samples (only 49 could be analyzed) were then compared to 101 matched 
controls. Indeed, cancer cases had significantly higher MN frequencies than 
controls, which indicates that MN can predict cancer [Murgia et al., 2008]. 
 
In a meta-analysis, results from 25 studies were evaluated for MN frequencies 
in untreated cancer patients. Compared to cancer-free controls, they had a 28 
to 64% higher rate of MN [Iarmarcovai et al., 2008]. 
 
In a study published in 2010, samples from 44 untreated cancer patients were 
compared to 40 disease-free controls. Mean MN frequencies were significantly 
higher in patients than in controls, independently from cancer sites [Milosevic-
Djordjevic et al., 2010]. 
 
In a recently published study, 346 patients with pancreatic cancer were 
compared to 449 healthy persons. MN frequencies of cancer patients were 
significantly higher than in controls, with a higher cancer risk in men than in 
women [Chang et al., 2011]. 
 
In another report, 59 patients with diagnosed head and neck cancer were 
compared to 34 healthy first-degree relatives (including parents, siblings or 
sons/daughters). Data were also collected from 31 healthy volunteers who did 
not have any cancer history in their families, and compared with cancer cases. 
Highest values for MN frequencies were found in cancer patients and were 
significantly higher than in relatives and controls [Burgaz et al., 2011]. 
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The findings from the presented studies give evidence that elevated frequencies 
of MN can be associated with an increased cancer risk and that the CBMN 
assay is a reliable tool for the cancer risk assessment. 
 
2.2.4.2 Bilirubin and DNA damage 
So far, only one study has analyzed micronuclei frequencies and compared 
them to elevated serum bilirubin levels. It should be noted that bilirubin 
concentrations were not measured, but indicated by UGT1A1 polymorphism. 
 
In this study it was hypothesized that UGT1A1 polymorphism, causing elevated 
bilirubin concentrations, can protect from oxidative damage. Individuals, who 
are homozygous for 7- and 8-TA repeat allele have a mild hyperbilirubinemia 
(Gilbert’s syndrome), while repeats of 5- and 6-TA does not cause elevated 
bilirubin concentrations. 101 healthy persons, aged between 19 and 53 years, 
were recruited and analyzed for UGT1A1 polymorphism. They measured 
kinetochore-positive and -negative MN frequencies in 63 subjects (48 smokers 
and 15 non-smokers) and found a trend indicating that individuals with lower 
bilirubin have higher kinetochore-positive MN frequencies, but not significantly 
[Grant et al., 2004]. 
 
Smoking can lower serum bilirubin concentrations and bilirubin concentrations 
were not directly measured, therefore, it is not possible to compare these 
results with the present study. Also, Grant et al. used a slightly different method 
for the MN measurement than at the present study. 
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3 MATERIALS and METHODS 
 
3.1 Study Design 
The aim of the present study was to establish whether the antigenotoxic effects 
of bilirubin prevent micronuclei formation in individuals with moderately elevated 
circulating serum bilirubin concentrations (Gilbert’s syndrome). This study had a 
cross-sectional design and was in total performed over a period of two years. 
There is little information on oxidative DNA damage in people with Gilbert’s 
syndrome (GS), therefore this study aimed to investigate levels of DNA stability 
in GS and matched control subjects (i.e. people with normal bilirubin 
concentrations). Furthermore, it was hypothesized that lymphocytes from GS 
subjects would be protected from free radical induced DNA damage due to 
elevated BR levels. The results were expected to show whether moderately 
increased unconjugated serum bilirubin levels have beneficial effects on 
biomarkers of oxidative damage. Additionally, oxidative stress, inflammation 
and cardiovascular disease related parameters as well as the nutritional status 
were measured. The links between these factors and DNA damage were also 
investigated. 
For the screening, blood was taken from the subjects after the patients 
agreement was filled. A questionnaire was administered, to check whether the 
subjects met the inclusion or exclusion criteria (see criteria below). When the 
subjects met the inclusion criteria, they were invited to give a second sample at 
the General Hospital Vienna (AKH). The participants were randomized in GS 
and controls. 
Participants were advised to fast and only ingest 400 kcal (between 9 am and 5 
pm, followed by an overnight fast), before the second, main blood collection. It 
is well known that as a consequence of fasting, serum bilirubin levels rise, 
especially in people with GS [Owens et al., 1973]. The next morning, blood, 
urine samples and buccal cells were collected. The blood samples were taken 
by a trained clinician at the AKH and were then transported to the Department 
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of Nutritional Sciences. Samples were continuously protected from light to 
prevent bilirubin oxidation. 
A coding system (e.g. GS_01 for first participant) was used to de-identify 
subjects and assisted in removing bias from the analysis. Researchers did not 
know whether subjects had high or low serum bilirubin concentrations. 
 
Study population 
This study was approved by the Human Ethics Research Committee of the AKH 
(Ref. No.: 274 / 2010). A patient agreement was issued to participants and they 
had to declare their approval. All samples were collected from April to 
September 2010. 
A total of 100 subjects, aged between 20 and 80 years, were recruited for the 
study. Participants were identified as GS, based on their serum unconjugated 
bilirubin concentrations >17.1 µmol/L (>1 mg/dL) determined by high-
performance liquid chromatography (HPLC). For the clinical definition of GS, 
normal serum liver enzyme activities and blood counts were required in addition 
to enhanced bilirubin levels. 45 of these participants were diagnosed with GS 
and 39 participants were then allocated into the control group. 16 subjects could 
not be assigned to one of the groups, due to their unclear bilirubin levels and 
were just included for statistical analysis using tertiles of bilirubin serum 
concentration. 
Subjects were recruited partly by doctors in the AKH and by advertisements 
posted in universities, pharmacies or hospitals, as well as on internet platforms 
and in newspapers. For their participation, subjects were refunded with € 50,-.  
 
Inclusion criteria 
 20 - 80 years 
 total serum bilirubin >20.52 µmol/L (>1.2 mg/dL) in GS subjects 
 unconjugated serum bilirubin >17.1 µmol/L (>1 mg/dL) in GS subjects 
 total serum bilirubin <20.52 µmol/L (<1.2 mg/dL) in controls 
 unconjugated serum bilirubin <17.1 µmol/L (<1 mg/dL) in controls 
 γ-glutamyltranspeptidase in blood <100 IU 
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 alanin-aminotransferase in blood <100 IU 
 aspartat-aminotransferase in blood <100 IU 
 moderate physical activity 
 
Exclusion criteria 
 younger than 20 years or older than 80 years 
 cardiovascular diseases 
 hepatitis B/C 
 any other liver diseases 
 cholelithiasis 
 hemolysis 
 chronic kidney diseases 
 past or present cancer 
 diabetes mellitus 
 supplementation with antioxidants in the past four weeks before the first 
blood sample 
 medication that influences liver values (e.g. Probenecid, Rifampicin) 
 people with organ transplants 
 current smoking (>5 cigarettes per day) 
 alcohol consumption (>7 drinks per week) 
 competitive athletes (>10 hours training per week) 
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3.2 HPLC analysis 
Bilirubin is sensitive to light and oxygen [Zelenka et al., 2008] therefore, all 
preparations had to be done fast and ideally under light protection. Whenever 
possible, dark tubes were used, closed immediately and serum was kept at 
4 °C. 
Bilirubin is known to have three isomers: IIIα, IXα, and XIIIα. The HPLC 
chromatogram shows one major peak, known as the IXα-isomer, and two 
smaller ones. According to Zelenka et al., in commercial bilirubin the IXα-isomer 
takes about 92% of the peak area, while bilirubin IIIα and bilirubin XIIIα have 
only 4 % each. This is as well valid for the analysis within this study and can be 
seen in Figure 6, which shows a chromatogram of a standard solution. By 
contrast, in human serum only IXα-bilirubin is detectable, as shown in Figure 7. 
The following method was modified from the HPLC protocol of Bulmer et al. 
(2008b). 
The serum unconjugated bilirubin concentration was quantified using HPLC and 
a photo diode array detector. The serum was separated using a C18 reverse 
phased column at a flow of 1 mL/min. From each sample and standards 50 µL 
were injected into HPLC column for separation. A retention time of 
approximately 12 minutes was obtained. Some of the samples, randomly 
chosen, were analyzed in duplicates. The evaluation was done via standard 
curve. 
3.2.1 HPLC, reagents and equipment 
HPLC adjustments, reagents and equipment are summarized in Table 1, Table 
2 and Table 3. 
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Table 1. HPLC adjustments. 
High-Performance Liquid Chromatography 
Pump LaChrom Elite, Hitachi L-2130 
Sampler LaChrom Elite, Hitachi L-2200, Auto-Sampler 4 °C, 
Injection Volume: 50 µL 
Oven LaChrom Elite, Hitachi L-2300 Column Oven, Temperature: 35 °C 
Detector SPD-M20A, Shimadzu, Photo diode array detector 
Wavelength 450 nm. Cell Temperature: 35 °C 
Column Fortis F18-050703 HPLC column, 4.6 x 150 mm, 3 µm 
Flow Rate 1.0 ml/min 
Pressure 160 bar (in average) 
Software EZ Chrome, Hitachi 
 
 
Table 2. Reagents for HPLC analysis. 
Name Manufacturer Factory number 
DMSO Sigma Aldrich D 4540 
Glacial acetic acid Sigma Aldrich A 9967-500G 
HPLC grade methanol (purity 99.9%) Sigma Aldrich 34860 
HPLC grade water Sigma Aldrich 95304 
Bilirubin (alpha) Frontier Scientific B 584-9 
N-dioctylamine Sigma Aldrich D 20 1146-100G 
 
 
Table 3.  Equipment for HPLC analysis. 
Name Manufacturer 
Blood collection tubes Vacuette® Greiner bio-one 
Centrifuge Thermo Scientific, Megafuge 40 
Centrifuge Eppendorf 5413R 
Microcentrifuge tubes, dark, 1.5 mL Eppendorf 
Ultrasound-bath Bandelin Sonorex RK 100 
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3.2.2 Preparation of mobile phase and standard solutions 
Mobile Phase 
The mobile phase for the HPLC-analysis was prepared as follows. 
150 mL of methanol were poured in a conical flask, placed on a scale and 
zeroed. As methanol evaporates, the next step had to be quick: 24.2 g 
dioctylamine were added to the methanol. For smaller amounts, a glass pipette 
was used. The dioctylamine starts to precipitate when it comes in contact with 
air. To minimize this reaction, the lid had to be put on as soon as finished. To 
avoid evaporation of methanol, the flask was covered with a parafilm, when 
finished with this step. Then, a small beaker was placed on the scale in the 
fume cupboard and zeroed. Using a glass pipette, 6.01 g of glacial acetic acid 
was added step by step to the methanol/dioctylamine-mixture. The reaction is 
exothermic which heats up the flask slightly. 800 mL of methanol were poured 
in a 1 L flask and the methanol/dioctylamine/acetic acid-mixture was added. 
Finally, 50 mL of HPLC grade water was added and all components were mixed 
together. 
 
Column activation 
The column was flushed by pure methanol about three to four hours, and then 
gradually mobile phase was added over a period of 15 to 20 minutes before 
100% mobile phase was reached. The column should run 100% mobile phase 
for three to four hours, before injecting the first sample. 
 
Preparation of standard solutions 
Exactly 5.85 mg of commercial bilirubin were weighed out on a small weigh 
boat. With a pipette bilirubin was transferred by DMSO into a 20 mL volumetric 
flask and exactly filled up to the mark. By gentle shaking and using the 
ultrasound bath all constituents were dissolved. The resulting concentration was 
500 µM and was equivalent to the standard solution one (S1). 
For all other dilutions the scheme, shown in Table 4, was followed and flasks 
were exactly filled up to the mark with DMSO. Bilirubin has its best solubility in 
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DMSO, is good soluble in chloroform and difficult in water, therefore, DMSO 
was used in the trial. 
 
Table 4. Scheme for standard solutions. 
Standard solution  [V] mL [c] µmol/l 
S1 5.85 mg bilirubin 20 500 
S2 2 mL S1 5 200 
S3 500 µL S2 1 100 
S4 250 µL S2 1 50 
S5 100 µL S2 1 20 
S6 100 µL S3 1 10 
S7 100 µL S4 1 5 
S8 100 µL S6 1 1 
 
 
160 µL of mobile phase was pipetted into dark tubes. 40 µL of the appropriate 
standard solution was added and vortexed for 30 seconds. 120 µL was 
transferred into HPLC glass vials with inlets. Until injection the vials were kept at 
4 °C in the dark, otherwise bile pigments would decompose. Standards were 
frozen at -80 °C until use on analyzing days. At least every 3 – 4 weeks, 
standards were prepared new, when the highest peak started loosing area 
(<90%). 
Figure 6 shows a HPLC chromatogram of a standard solution with a 
concentration of 100 µmol/L. 
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 Retention time Area Area Percent 
IIIα-bilirubin 10.376 123289 3.338 
IXα-bilirubin 10.941 3426320 92.756 
XIIIα-bilirubin 11.560 144312 3.907 
Totals  3693921 100.00 
Figure 6. HPLC chromatogram of a standard solution [100 µmol/L]. 
 
3.2.3 Sample preparation 
Blood samples were collected by venipuncture at the AKH in Vacuette® tubes 
between 8 and 10 am each day and stored in a dark cool place. Samples were 
transported to university and centrifuged at 3000 RPM for 10 minutes at 4 °C to 
separate serum from other blood components. 
Serum from a healthy person served as a control. The bilirubin level of this 
control was 4.57 µmol/L and aliquot samples were stored at -80 °C. On days of 
blood collection a control aliquot was defrosted and analyzed with HPLC 
together with the samples of the study subjects. The serum of each sample was 
transferred into dark tubes and remaining serum was fumigated with nitrogen 
and frozen at -80 °C. 160 µL of mobile phase were put into dark tubes, 40 µL of 
serum was added and vortexed for 30 seconds. These tubes were centrifuged 
at 14000 RPM for 5 minutes at 4 °C. After that, 120 µL of the supernatant was 
IIIα 
IXα 
XIIIα 
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transferred into HPLC glass vials with inlets. Until injection, vials were kept at 
4 °C in the dark, to prevent decomposing of the bile pigments.  
Humans show only the IXα-bilirubin isomer on HPLC chromatograms. Figure 7 
shows the chromatogram of a GS subject with a unconjugated bilirubin 
concentration of 74.65 µmol/L. 
 
 Retention time Area Area Percent 
IIIα-bilirubin - - - 
IXα-bilirubin 10.984 2730669 99.823 
XIIIα-bilirubin - - - 
Totals  2735512 100.00 
Figure 7. HPLC chromatogram of a GS subject [74.65 µmol/L]. 
 
3.2.4 Reproducibility 
The coefficient of variation for this method was tested with the control serum 
and calculated as shown in the equation below with Microsoft Excel. The 
intraday variation after 10 control samples was 1.57%. The interday variation 
throughout the whole analysis from April to September was 5.71%. 
 
Coefficient of variation = (standard deviation / average of samples) x 100% 
IXα 
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3.2.5 Statistical analysis 
The concentration of unconjugated bilirubin of all study subjects was calculated 
with Microsoft Excel, using the linear plot from May 10, 2010 with R² = 0.9999 
and y = 36578x (Figure 8). Average, standard deviation and coefficient of 
variation were calculated with Excel. 
 
Concentration x [µmol/L] = area IXα-bilirubin / k 
 
 
Linear plot of unconjugated bilirubin
y = 36578x
R2 = 0,9999
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Figure 8. Linear plot of bilirubin used for analysis, done in May 2010. 
 
 
Data were analyzed with the Statistical Programme for Social Sciences (SPSS) 
version 17.0. Data were tested for normal distribution by Kolmogorow-Smirnov 
Test. As unconjugated bilirubin did not show normal distribution, the Mann-
Whitney-U-Test was the alternative to the T-test. Bilirubin tertiles were analyzed 
with the Kruskal-Wallis-H-Test. Data are shown as mean ± standard deviation. 
P <0.05 was considered as significant and marked with *. 
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3.3 Cytokinesis-block micronucleus assay 
The method of the cytokinesis-block micronucleus (CBMN) cytome assay was 
adapted from Fenech (2007). 
With the CBMN cytome assay chromosome breakage, DNA misrepair, 
chromosome loss, non-disjunction, necrosis, apoptosis and cytostasis can be 
measured in human lymphocytes. DNA damages appear in the assay as 
micronuclei (MN), nucleoplasmic bridges (NPB) and nuclear buds (NBUD). MN 
are expressed in binucleated (BN) cells that are once-divided due to blocking 
cytokinesis with cytochalasin-B. 
 
3.3.1 Reagents and equipment 
All reagents and the equipment used for the assay are summarized in Table 5 
and Table 6. 
 
Table 5. Reagents used in the cytokinesis-block micronucleus assay. 
Name Manufacturer Factory number 
Cytochalasin-B Sigma Aldrich C 6762 
Diff-Quick Staining Set Medion 
Diagnostics 
460.058 
DMSO Sigma Aldrich D 4540 
Entellan Merck 1.07961.0100 
Fetal Bovine Serum “Gold”, heat inactivated PAA A 15-152 
L-Glutamine Sigma Aldrich P 7513 
PBS Sigma Aldrich D 8537 
PHA PAA J01-006 
RPMI PAA E15-039 
Sodium pyruvate Sigma Aldrich P 2256 
Trypanblue Sigma Aldrich T 8154 
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Table 6. Equipment used in the cytokinesis-block micronucleus assay. 
Name Manufacturer 
Blood collection tubes, Vacuette® Greiner bio-one 
Centrifuge Eppendorf 5413R 
Centrifuge Thermo Scientific, Megafuge 40 
Cytocentrifuge Thermo Scientific, Cytospin 4 
Cell counter Invitrogen 
Centrifuge tubes, Leucosep® Greiner bio-one 
Microscope Olympus 
 
 
3.3.2 Sample preparation 
3.3.2.1 Blood collection 
Blood samples were collected by venipuncture at the AKH in Vacuette® tubes 
between 8 and 10 am each blood sampling day and stored in a dark cool place. 
Samples were transported to the university for further preparations.  
All steps were done under sterile conditions in the laminar flow and sterile 
equipment was used until slide centrifugation. 
 
3.3.2.2 Culture medium 
The medium for lymphocytes cultivation was prepared by adding 30 mL RPMI + 
3.3 mL FBS + 330 µL sodium pyruvate + 330 µL L-glutamine into a sterile 
45 mL centrifuge tube. 
 
3.3.2.3 Isolation of lymphocytes 
9 mL heparinized blood was transferred carefully with a Pasteur pipette from the 
blood collecting tube into the ficoll-containing Leucosep® tube. The tubes were 
centrifuged at room temperature for 15 minutes at 1036 x g without brake. 
After centrifugation, a sequence of layers occurred (Figure 9):  
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From top to bottom: 
a) plasma 
b) enriched cell fraction (interphase consisting of lymphocytes / PBMCs) 
c) separation medium 
d) porous barrier 
e) separation medium 
f) pellet (erythrocytes and granulocytes). 
 
Figure 9. Sequence of layers after centrifugation [Greiner-Bio One, 2011]. 
 
From now on, all steps were done on ice. The enriched cell fraction 
(lymphocytes / PBMCs) was harvested by a sterile plastic Pasteur pipette into a 
15 mL centrifugation tube. The cell suspension was washed with 15 mL of 
cooled PBS and subsequently centrifuged for 10 minutes at 250 x g and 
supernatant was aspirated by sterile glass Pasteur pipette. This washing step 
was repeated once and the cell pellet was resuspended in 1 mL of cool PBS. 
3.3.2.4 Cell counting 
10 µL of diluted cell suspension in PBS were mixed with 10 µL trypanblue, 
transferred onto a slide and measured by a cell counter. With countess, the cell 
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number of viable cells was determined (living cells / mL). Tubes with PBS cell-
fraction were centrifuged again and medium was added (~1 mL). 
 
 
 
3.3.2.5 Incubation and addition of PHA 
In total, a volume of 750 µL with a concentration of 106 cells/mL was needed. 
Therefore, adequate µL of cell suspension + RPMI were added in a cell culture 
tube. Samples were prepared in duplicates (A + B). 
By adding 15 µL of PHA the mitotic division of lymphocytes was stimulated. 
Cells were incubated with lids loose at 37 °C, 5 % CO2 for exactly 44 hours. 
 
3.3.2.6 Addition of cytochalasin-B after 44 hours 
Stock solution of cytochalasin-B in DMSO [600 µg/mL] was diluted to the 
concentration needed [60 µg/mL] by adding 200 µL stock + 20 µL stock + 
1980 µL RPMI. 
56.2 µL medium from the supernatant of the culture were removed and replaced 
with 56.2 µL of diluted cytochalasin-B. Adding cytochalasin-B stopps cell 
division. Cultures were incubated at 37 °C, 5 % CO2 for further 28 hours. 
 
3.3.2.7 Harvesting of cells after 72 hours 
Slides were labelled, and with filter-cards and cones placed in the 
cytocentrifuge. 
200 µL of the supernatant were taken off and cell suspension was mixed gentle 
by tapping the tube with the finger. 46 µL DMSO were added and mixed again 
by finger tapping. 120 µL were transferred directly to the cytocentrifuge cones. 
From each tube two slides were prepared (a + b).  
Isolation of 
lymphocytes 
Preparation 
of slides 
Addition of 
cytochalasin-B 
Addition of 
PHA 
0h 44h 72h INCUBATION INCUBATION 
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Cytocentrifugation was performed at room temperature for 5 minutes at 
600 RPM, at high acceleration. Subsequently, slides were air-dried for exactly 
10 minutes. If slides dry longer, the morphology of cells changes, which makes 
it difficult to score. 
 
3.3.2.8 Staining of cells 
Slides were placed vertically in a dry staining rack and placed in staining 
solutions: 
Diff-Quick fixative: 10 minutes 
Diff-Quick solution 1 (red): dipping 10 times 
Diff-Quick solution 2 (blue): dipping 8 times.  
Keeping the slides in the rack, they were washed gently with tap water and 
rinsed with pure water, to get rid of dye. Then, slides were placed on paper 
tissues and dried for about 10-15 minutes. Slides were left to dry completely for 
at least 30 minutes before putting cover slips on. At maximum, they were left to 
dry overnight at room temperature. 
 
3.3.2.9 Cover slipping and storage 
2-3 drops of entellan were put on the slides next to the spot (not directly on the 
spot) and a coverslip was placed above it. Slides were dried overnight and 
finally stored in slide boxes. Per subject, four slides were prepared (Aa, Ab, 
Ba,Bb). 
 
3.3.3 Scoring of cells 
The scoring was done with a light microscope at x1000 magnification. 
In the CBMN cytome assay mononucleated, binucleated and multinucleated 
viable cells, necrotic and apoptotic cells were scored, as well as the frequency 
of DNA damage biomarkers (MN, NPB and NBUD). In total, 2000 BN cells were 
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scored per subject, per slide 500 BN. For each slide, the following scheme was 
obtained: 
 
Until 250 BN cells, all parameters were scored: 
 Mononucleated cells (MONO) 
 Binucleated cells (BN) 
 Multinucleated cells (MULT) 
 Apoptotic cells 
 Necrotic cells 
 BN with MN 
 Total amount of MN in BN 
 BN with NPB 
 BN with NBUD 
 
After 250 BN, only BNs were considered and counted until 500 BN: 
 BN 
 BN with MN 
 Total amount of MN 
 BN with NPB 
 BN with NBUD 
 
Slides were scored as described by Fenech. For a detailed description of 
scoring criteria see Fenech et al. (2003) and Fenech (2007). Pictures below 
illustrate examples of the cells. 
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Mononucleated cells Binucleated cells  Multinucleated cells 
   
 
Apoptotic cells    Necrotic cells 
 
 
BN with MN 
     
 
BN with NPB 
   
 
BN with NBUD 
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3.3.4 Data calculation 
Results of the counting were entered into the scoring sheet and calculated with 
Microsoft Excel. For every subject, every parameter gives four different data, of 
which the average can be calculated. 
 
Total amount of cells scored: 
MONO+ BN + MULT + Apo + Necro 
 
 
Frequency of cells in %: 
BN / total amount of cells scored * 100 
Apo / total amount of cells scored * 100 
Necro / total amount of cells scored * 100 
 
 
Nuclear Division Index (NDI) [Fenech, 2000]: 
(MONO + 2xBN + 4xMULT) / viable cells (MONO + BN + MULT) 
 
 
Nuclear Division Cytotoxicity Index (NDCI) [Fenech, 2000]: 
(Apo + Necro + MONO + 2xBN + 4xMULT) / total amount of cells scored 
 
 
MN, NPB and NBUD per 1000 BN: 
BN with MN / BN * 1000 
MN / BN * 1000 
NPB / BN * 1000 
NBUD / BN * 1000 
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Anticipated results: Fenech (2007) gives the following ranges of values to 
expect from the CBMN assay: 
Frequency of BN: 30–60 % 
NDI: 1.3–2.2 
Necrotic cells: 0–9 % 
Apoptotic cells: 0–7 % 
MN per 1000 BN: 0–30 
NPB per 1000 BN: 0–10 
NBUD per 1000 BN: 0–5 
 
3.3.5 Statistical analysis 
Data were analyzed with SPSS 17.0. Data were tested for normal distribution 
with the Kolmogorow-Smirnov Test. As data were not normally distributed, the 
Mann-Whitney-U-Test was the choice. When more than two groups were 
compared, the Kruskal-Wallis-H-Test was used. P< 0.05 was considered 
significant and marked with *. 
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4 RESULTS and DISCUSSION 
 
4.1 Bilirubin analysis and validation 
In total, 100 subjects, including 70 males and 30 females, completed the study. 
On average, the mean age of the population was 31.6 ± 11.8 years, with a 
range between 20 and 70 years. The average unconjugated serum bilirubin 
concentrations and averages are shown in Table 7. 
 
Table 7. Average concentrations and ranges of unconjugated bilirubin in the study population. 
 Number UCB [µmol/L] Ranges of UCB 
[µmol/L] 
Total study population 100 20.44 ± 15.14 4.10 – 73.53 
Men 70 23.05 ± 16.07 4.28 – 73.53 
Women 30 14.34 ± 10.65 4.10 – 41.21 
 
Unconjugated serum bilirubin from the study subjects was determined by HPLC. 
The control serum was obtained from a healthy person. The interday variation 
showed the mean of the control serum values measured on each blood 
sampling day (14 days in total). This coefficient should illustrate stability of the 
method and of the frozen samples. For the intraday variation a serum sample 
was analyzed 10 times to show quality and precision of the method. Interday 
and intraday variations are presented in Table 8. 
 
Table 8. Interday and intraday variation of unconjugated bilirubin. 
 Number Mean 
[µmol/L] 
SD CV (%) 
Interday variation 14 4.58 0.26 5.71 
Intraday variation 10 5.08 0.08 1.57 
 
The control serum was filled in dark cups and frozen immediately at -80°C and 
one cup was thawed for each analyzing day. Figure 10 shows the good stability 
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of the frozen samples throughout the whole analysis, lasting from April to 
October. Concentrations ranged between 3.98 and 4.99 µmol/L. 
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Figure 10. Concentrations of serum control sample over six months. 
 
 
Although bilirubin is unstable and sensitive to light, these results show that a 
careful treatment (dim light, fast procedure, frozen immediately) can prevent 
bilirubin from degradation for a quite long time. Concentrations stayed relatively 
stable enabling a repeat of the analysis even after some months. 
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4.2 Micronucleus assay 
Data from the CBMN assay were collected from 98 subjects (two values were 
excluded from the statistical analysis because of extreme MN values). 
The average frequencies of MN, NPB and NBUD in the study population were 
11.8 ± 9.1; 1.3 ± 1.3 and 2.9 ± 2.2. These values were in the ranges of the 
anticipated results suggested by Fenech (2007) and cell counting was based on 
the instructions from the HUMN project [Fenech et al., 2003]. Therefore, the 
data can be regarded as highly valuable and comparable to other projects. 
 
In the present study, research was focused on the influence of unconjugated 
bilirubin on DNA. It was proposed that people, affected by the Gilbert’s 
syndrome and therefore having elevated bilirubin concentrations, have less 
DNA damage (MN, NPB and NBUD) than persons with normal bilirubin 
concentrations. The population was divided into three similar groups (tertiles), 
based on their HPLC determined unconjugated serum bilirubin concentrations. 
The following results compare these three groups. 
 
Data are presented in box plot diagrams. The box includes the average 50% of 
all data. The length of the box corresponds to the interquartile range. The line in 
the box represents the median and gives information about the skewness. The 
lines outside of the box are called whisker and describe data outside the 50%. 
Dots display outliers, stars show extreme values. 
 
Table 9 summarizes the results of the CBMN assay in three bilirubin groups. 
There were no significant differences found between the groups. MN values did 
hardly differ and NPB decreased slightly with higher bilirubin concentrations. 
NBUD showed and increasing tendency, which is inconsistent with the 
hypothesis that UCB can protect from DNA damage. This trend is displayed in 
Figure 11. 
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Table 9. Chromosomal damage measured by the CBMN assay of study subjects in bilirubin 
tertiles. 
 Tertile 1:  
4.10–11.12 
µmol/L 
Tertile 2: 
11.29–20.69 
µmol/L 
Tertile 3: 
20.86–73.53 
µmol/L 
pValue 
Number 33 34 33 - 
Age [years] 30.64 ± 11.25 29.94 ± 10.50 34.39 ± 13.34 0.202 
MN total in BN/1000 BN 11.03 ± 9.11 12.24 ± 9.05 12.22 ± 9.30 0.789 
BN with MN/1000 BN 11.72 ± 12.05 10.67 ± 6.74 10.68 ± 7.21 0.896 
BN with NPB/1000 BN 1.34 ± 1.33 1.32 ± 1.27 1.09 ± 1.38 0.365 
BN with NBUD/1000 BN 2.34 ± 1.45 3.00 ± 2.20 3.37 ± 2.76 0.576 
 
 
Figure 11. NBUD in BN/1000 BN in bilirubin tertiles. 
 
Although the mean values of NBUD tended to increase with higher bilirubin 
concentrations, the median in the boxplot is decreased. The variability was 
much larger in tertile 3 than in tertile 1, suggesting that there were subjects with 
relatively inconsistent NBUD values. 
NBUD are assumed to represent amplified DNA, which is removed during the S 
phase of the cell cycle, but they may also arise after exposure to γ-irradiation. 
Most NBUD are formed from interstitial or terminal acentric fragments, which 
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might refer to nuclear membranes of DNA left in the cytoplasm, however, the 
process of NBUD formation is not fully understood yet [Fenech et al., 2011]. 
Therefore, only a few studies presented data of NPB and NBUD so far, making 
it almost impossible to interpret these findings. Generally, it is difficult to 
compare total values of the CBMN assay, as there are a lot of influencing 
factors (e.g. counters, conditions). But most studies used the same method, 
previously described by Fenech (2007), therefore tendencies can be evaluated 
quite well. 
 
Coskun et al. (2011) compared CBMN frequencies of pesticide exposed 
farmers to controls. The total frequencies for NBUD were 0.31 ± 0.13 for 
controls and 1.22 ± 0.21 for farmers, suggesting higher DNA damage in the 
exposed subjects. However, our mean values of NBUD increased with higher 
bilirubin concentrations, which seems to be inconsistent with our hypothesis that 
DNA is protected by higher bilirubin levels. Consequently, more research on the 
effects of bilirubin in relation with the micronucleus assay is needed. To the best 
of our knowledge, only one study (Grant et al., 2004) focused on bilirubin and 
MN frequencies. However, this group did not measure bilirubin concentrations, 
but detected the UGT1A1 polymorphism, which causes elevated bilirubin levels. 
Moreover, they used a slightly different method. Given that, they could not show 
a protecting effect of bilirubin either. Grant et al. suggested that bilirubin might 
not work as an antioxidant in lymphocytes or that a higher amount of oxidative 
stress would be needed, to be able to measure a protecting outcome. 
Additionally, 48 of the 63 subjects were smokers, and smoking is assumed to 
lower the antioxidant effect of bilirubin [Schwertner, 1998], so this might have 
influenced the results from Grant et al. In our study, smokers were excluded to 
avoid this effect, but there was still no protective influence on DNA measurable. 
However, it might be possible to measure the DNA protecting properties of 
antioxidants with the CBMN assay. In a study by Fenech et al. (2005) the effect 
of dietary intake on MN formation was investigated in 190 healthy subjects. Five 
micronutrients could be identified to have a decreasing potential on DNA 
damage. Vitamin E, retinol, folate, nicotinic acid and calcium could reduce MN 
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frequencies. As vitamin E is an antioxidant of high potential, this study showed 
that antioxidants had a positive effect on DNA stability. It was suggested that 
vitamin E might protect DNA from mutation triggered by reactive oxygen 
species. Bilirubin is assumed to be an antioxidant as strong as vitamin E 
[Stocker et al., 1987], therefore, we could have expected a lower DNA damage 
in the Gilbert’s syndrome group. Hence, the present results showed that UCB 
did not have a significant effect on the formation of DNA damage. However, this 
was the first study that examined a relationship of bilirubin concentrations and 
DNA damage, consequently more research is needed. 
 
4.2.2 Influencing factors 
4.2.2.1 Age 
 
 Age in tertiles 
 
Table 10. DNA damage of study subjects in age tertiles. 
 Tertile 1:  
20-24 years 
Tertile 2:  
25-32 years 
Tertile 3: 
33-70 years 
pValue 
Number 32 32 34 - 
UCB [µmol/L] 18.96 ± 14.29 19.44± 13.88 22.82 ± 17.14 0.690 
MN total in BN/1000 BN 7.40 ± 3.17 9.68 ± 7.59 18.24 ± 10.71 0.000*** 
BN with MN/1000 BN 6.90 ± 3.03 8.56 ± 5.22 17.20 ± 11.64 0.000*** 
BN with NPB/1000 BN 1.06 ± 1.19 1.40 ± 1.54 1.29 ± 1.22 0.479 
BN with NBUD/1000 BN 2.06 ± 1.50 2.90 ± 1.97 3.70 ± 2.71 0.024* 
 
Significant differences were found in MN and NBUD (Table 10); these results 
are displayed in boxplots (Figure 12 and Figure 13). Total MN and BN with MN 
in tertile 3 were significant higher than tertile 2 and 1 (3>2>1), in NBUD tertile 3 
was only significant with tertile 1. 
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Figure 12. Total MN in BN/1000 BN in age tertiles. 
 
 
Figure 13. NBUD in BN/1000 BN in age tertiles. 
 
Age was highly significant with MN and NBUD. With increasing age, more MN 
and NBUD were found, indicating an influence of aging. Additionally, the 
median increased with age, both in MN and NBUD and in both cases the 
variability was largest in the oldest group. Especially, MN showed a wide 
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variability in tertile 3 compared to the younger ones, which suggests that there 
were some people with quite high MN frequencies as well as with low ones. 
 
The increase of MN with age is in agreement with other authors. Wojda et al. 
(2007) described a higher frequency of MN in older people. Bonassi et al. 
(2001) reported that people aged over 40 years had more MN. Mateuca et al. 
(2006) showed that MN frequencies rose with age. Garaj-Vrhovac et al. (2008) 
showed that subjects under 30 years had the lowest MN median values and 
frequencies were increasing from then on. 
MN increase with age for many reasons, an unhealthy lifestyle can be named 
as a general cause, but also the exposure to toxic compounds. A poor diet, 
stress, sickness, alcohol and physical activity can also cause elevated 
chromosomal damage [Fenech & Bonassi, 2011]. Although a few studies 
showed data for NPB and NBUD [Coskun et al., 2011; Garaj-Vrhovac et al., 
2008], no influence of age was presented in these markers. 
 
 
 Age in two groups and in bilirubin tertiles 
 
Table 11. DNA damage of study subjects in two age groups and in bilirubin tertiles. 
  20-29 years 30-70 years pValue 
Tertile 1 Number 22 10 - 
 UCB [µmol/L] 7.66 ± 2.11 7.35 ± 1.76 0.709 
 MN total in BN/1000 BN 7.59 ± 3.73 19.44 ± 12.74 0.002** 
 BN with MN/1000 BN 7.09 ± 3.54 21.90 ± 17.43 0.001*** 
 BN with NPB/1000 BN 1.32 ± 1.58 1.40 ± 0.51 0.130 
 BN with NBUD/1000 BN 2.04 ± 1.55 3.00 ± 0.94 0.062 
Tertile 2 Number 21 13 - 
 UCB [µmol/L] 16.09 ± 3.20 14.31 ± 3.05 0.184 
 MN total in BN/1000 BN 9.14 ± 5.46 17.23 ± 11.47 0.019* 
 BN with MN/1000 BN 8.57 ± 5.35 14.07 ± 7.53 0.020* 
 BN with NPB/1000 BN 1.47 ± 1.47 1.07 ± 0.86 0.683 
 BN with NBUD/1000 BN 2.52 ± 1.88 3.77 ± 2.52 0.198 
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Tertile 3 Number 16 16 - 
 UCB [µmol/L] 38.87 ± 11.98 38.07 ± 13.77 0.705 
 MN total in BN/1000 BN 6.81 ± 2.71 17.62 ± 10.44 0.001*** 
 BN with MN/1000 BN 6.43 ± 2.47 14.93 ± 7.92 0.001*** 
 BN with NPB/1000 BN 0.93 ± 1.06 1.25 ± 1.65 0.842 
 BN with NBUD/1000 BN 2.50 ± 1.63 4.25 ± 3.37 0.198 
 
 
Figure 14. Total MN in BN/1000 BN in two age groups and in bilirubin tertiles. 
 
MN frequencies were significantly higher in the oldest group (see Table 11 and 
Figure 14). NPB and NBUD tended to be higher as well, but not with statistical 
significance. While NBUD were significant in age tertiles (Table 10 and Figure 
13), this effect was not measurable in two age groups (Table 11). In this 
analysis, data were also split in bilirubin tertiles, but there was no significant 
effect of bilirubin. However, the mean values of MN frequencies were lower in 
tertile 2 and 3 in the older group than in tertile 1, while NBUD were highest in 
the old group with high bilirubin concentrations. These results might indicate 
that an unconjugated bilirubin concentration of 11.29 µmol/L and higher can 
prevent from chromosomal damage. Further observations in an older population 
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with Gilbert’s syndrome are needed to clarify whether a longer exposure to 
bilirubin has a protective effect. 
 
Figure 15. Correlation of total MN in BN/1000 BN and age. 
 
Strong correlations were found in age and MN (Figure 15), in the whole study 
population (r=0.524; p=0.000) and in both genders (men: r=0.424; p=0.000; 
women: r=0.729; p=0.000). This result indicates that MN increased with age 
which is in agreement with the literature (see discussion before). 
 
4.2.2.2 Gender 
 
Table 12. DNA damage of study subjects in men and women. 
 Men Women pValue 
Number 70 30 - 
UCB [µmol/L] 23.05 ± 16.07 14.34 ± 10.65 0.002** 
Age [years] 31.13 ± 11.71 32.83 ± 12.09 0.630 
MN total in BN/1000 BN 10.29 ± 7.76 15.68 ± 10.93 0.012* 
BN with MN/1000 BN 8.98 ± 5.60 15.86 ± 12.72 0.004** 
BN with NPB/1000 BN 1.27 ± 1.42 1.20 ± 1.05 0.723 
BN with NBUD/1000 BN 2.91 ± 2.19 2.89 ± 2.33 0.924 
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The influence of gender was significant in UCB and MN frequencies (Table 12). 
 
Figure 16. Bilirubin concentrations in men and women. 
 
UCB was significantly higher in men than in women (p=0.002). There was a 
greater variability in men than in women, which might be due to the fact that 70 
men but only 30 women were included in the trial (Figure 16). Subjects with 
high bilirubin concentrations (>17.1 µmol/L) were diagnosed with Gilbert’s 
syndrome. It is known that this disease affects more men than women (12.4 vs. 
4.8%), and mean serum bilirubin concentrations are significantly higher in men. 
One explanation for this observation suggests that men have more bilirubin per 
kilogram body weight and they are generally heavier than women. Another 
explanation is the different hormonal balance, causing androgen steroid 
inhibition of bilirubin enzymatic glucuronidation [Radu & Atsmon, 2001]. 
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Figure 17. Total MN in BN/1000 BN in men and women. 
 
MN frequencies were significantly higher in women (p = 0.012; see Figure 17), 
which is in agreement with other authors [Bonassi et al., 2001; Costa et al., 
2007; Mateuca et al., 2006; Wojda et al., 2007]. It was assumed that the X 
chromosome gets lost as MN more often than other chromosomes. As women 
have two X chromosomes and men have only one, it is believed that this might 
be the reason for higher MN frequencies in women. [Fenech & Bonassi, 2011]. 
However, this should not indicate that women generally have a higher cancer 
risk than men. 
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4.2.2.3 Vitamins 
 
 Folic acid 
 
Table 13. DNA damage of study subjects in folic acid tertiles. 
 Tertile 1: 
38.90- 
72.80 ng/mL 
Tertile 2: 
74.10-
152.40 ng/mL 
Tertile 3: 
157.10-
510.40 ng/mL 
pValue 
Number 31 32 30 - 
UCB [µmol/L] 21.68 ± 13.31 21.13 ± 17.06 19.53 ± 15.96 0.395 
Age [years] 34.39 ± 11.01 35.03 ± 13.95 24.66 ± 6.75 0.000*** 
MN total in BN/1000 BN 13.19 ± 9.99 13.03 ± 9.50 8.76 ± 5.64 0.102 
BN with MN/1000 BN 11.22 ± 7.12 13.22 ± 11.83 8.13 ± 4.83 0.109 
BN with NPB/1000 BN 1.39 ± 1.74 1.50 ± 1.07 0.93 ± 1.04 0.053 
BN with NBUD/1000 BN 3.55 ± 2.79 3.22 ± 2.12 2.16 ± 1.31 0.092 
 
 
Figure 18. Folic acid concentrations in age tertiles. 
 
As illustrated in Table 13, highest folate concentrations were measured in the 
youngest age group. To display these results in a boxplot, age tertiles from 
Results and Discussion 
 
 63 
 
above were used. Folic acid concentrations were then classified as follows: 
tertile 1: 209.05 ± 121.59 ng/mL, tertile 2: 135.89 ± 119.06 ng/mL and tertile 3: 
81.78 ± 34.14 ng/mL (p = 0.000). The median decreased with age of the 
subjects. Also, the variability is very small in the oldest group, suggesting a 
homogeneous group (Figure 18). Tertile 3 was significant with tertile 2 and 1 
(3<2<1). 
 
 
Figure 19. Correlation of folic acid and age.  
 
Folic acid and age correlated significantly (Figure 19) in the whole study 
population (r = -0.496; p = 0.000), in men (r = -0.522; p = 0.000) and in women 
(r = -0.467; p = 0.012) in a negative way. 
 
Folic acid also correlated significantly with total MN (Figure 20) in the whole 
study group (r = -0.221; p = 0.035) and in women (r = -0.497; p = -0.010) 
negatively. High folic acid concentrations caused a lower MN frequency, 
suggesting DNA protection by this nutrient. 
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Figure 20. Correlation of total MN in BN/1000 BN and folic acid. 
 
Folate intakes >200 µg/day were recommended to secure chromosomal 
stability [Fenech et al., 2005]. The D-A-CH (Germany-Austria-Switzerland) 
reference values even recommend 400 µg/day [Elmadfa et al., 2009]. No 
significances were found with DNA damage markers, but there was a trend with 
less chromosomal damage in the group with highest folic acid concentrations. In 
tertile 3, MN, NPB and NBUD were lowest, suggesting a DNA protecting effect 
of folic acid. As the group with high folic acid concentrations was also the 
youngest, it is hard to say if the influence of age or folic acid was the dominant 
one. However, it is commonly known that folic acid is an important nutritive 
substance for cell division and DNA stability. Deficiencies cause 
hypomethylation of DNA leading to incorporation of uracil instead of thymine in 
the DNA, leading to DNA damage [Fenech, 2001]. In another study by Fenech 
et al. (2005) folate had been identified as one of five micronutrients exerting a 
lowering effect on MN formation. Given that, our results showed that folic acid 
protects the DNA. 
 
 
 
Results and Discussion 
 
 65 
 
 Vitamin B12 (cobalamin) 
 
Table 14. DNA damage of study subjects in vitamin B12 tertiles. 
 Tertile 1: 
1.10-1.40 
pM/L 
Tertile 2: 
1.50-2.10 
pM/L 
Tertile 3: 
2.20-3.90 
pM/L 
pValue 
Number 37 28 29 - 
UCB [µmol/L] 1.22 ± 0.98 1.32 ± 0.84 1.08 ± 0.85 0.176 
Age [years] 33.51 ± 13.30 31.24 ± 10.99 28.53 ± 10.35 0.156 
MN total in BN/1000 BN 13.14 ± 7.40 10.25 ± 7.23 10.96 ± 11.37 0.016* 
BN with MN/1000 BN 13.38 ± 10.21 9.03 ± 5.15 9.27 ± 8.76 0.006** 
BN with NPB/1000 BN 1.70 ± 1.37 1.14 ± 1.53 0.86 ± 0.87 0.003** 
BN with NBUD/1000 BN 3.89 ± 2.19 2.86 ± 2.24 1.86 ± 1.77 0.000*** 
 
In contrast to previously discussed folic acid, vitamin B12 showed significances 
with MN, NPB and NBUD (Table 14). All three markers were lower at high 
vitamin B12 concentrations. Medians were increasing with higher 
concentrations (Figure 21, Figure 22 and Figure 23). These results suggest a 
high influence of this vitamin on DNA stability and protection.  
 
Figure 21. Total MN in BN/1000 BN in vitamin B12 tertiles. 
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Figure 22. NPB in BN/1000 BN in vitamin B12 tertiles. 
 
 
 
Figure 23. NBUD in BN/1000 BN in vitamin B12 tertiles. 
 
In NPB and NBUD tertile 3 was significant with tertile 1. 
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Figure 24. Correlation of NBUD in BN/1000 BN and vitamin B12. 
 
Vitamin B12 correlated significantly with NBUD (Figure 24) in a negative way in 
the whole study population (r = -0.452; p = 0.000) and in men (r = -0.500; 
p = 0.000). Therefore, we conclude that high concentrations of vitamin B12 
prevent from NBUD formation. 
 
Along with folic acid, also vitamin B12 is involved in maintaining DNA stability. 
Both micronutrients are important for the synthesis of methionine and S-
adenosyl methionine (SAM). Vitamin B12 deficiencies and low methionine 
concentrations reduce SAM synthesis, leading to uracil incorporation into DNA 
[Fenech, 2001]. According to the Austrian Nutrition Report from 2008, the 
Austrian population is quite well supplied with this nutrient [Elmadfa et al., 
2009]. Several studies measured MN frequencies in relation to folic acid and 
vitamin B12 [Stopper et al., 2008; Minozzo et al., 2010; Milic et al., 2010]. To 
our mainly male study population were the results of Milic et al. (2010) most 
comparable, as in this study, 36 healthy males were investigated. Milic et al. 
showed that persons with the lowest vitamin B12 concentrations had the 
highest values of MN, what is exactly what we have found. 
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4.2.2.4 Influences within DNA damage markers 
 
 
Figure 25. Correlation of total MN in BN/1000 BN and NBUD in BN/1000 BN. 
 
DNA damage markers also showed significant correlations among each other. 
For example, total MN and NBUD correlated highly significantly (Figure 25) in 
the whole study population (r = 0.426; p = 0.000) as well as in men (r = 0.397; 
p = 0.001) and in women (r = 0.489; p = 0.008). Same results for correlations 
had been shown previously by Coskun et al. (2010) in pesticide exposed 
farmers. The authors suggested that besides clastogenic and aneugenic 
effects, pesticides might cause additional gene amplification. However, there is 
too little information to give assumptions about this relationship. Due to the 
different origin of chromosomal damage markers the influence of pro-oxidants is 
still unknown and further investigations are needed. Especially on NBUD and 
NPB less data are available yet. 
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4.2.3 Correlations 
Table 15. Correlations of all study variables. 
 UCB Age MN total in BN BN with MN BN with NPB BN with NBUD Folicacid 
Age 0.129 (0.202) - - - - - - 
MN total in BN 0.068  
(0.509) 
0.524 (0.000***) - - - - - 
BN with MN 0.053  
(0.607) 
0.545 (0.000***) 0.990 (0.000***) - - - - 
BN with NPB -0.059  
(0.561) 
0.083 (0.419) 0.272 (0.007**) 0.298 (0.003**) - - - 
BN with NBUD 0.103  
(0.311) 
0.273 (0.007**) 0.426 (0.000***) 0.462 (0.000***) 0.545 (0.000***) - - 
Folic acid -0.125  
(0.229) 
-0.496 (0.000***) -0.221 (0.035*) -0.207 (0.046*) -0.074 (0.482) -0.205 (0.049*) - 
Vitamin B12 -0.052  
(0.618) 
-0.196 (0.055) -0.262 (0.011*) -0.288 (0.005**) -0.339 (0.001**) -0.452 (0.000***) -0.089 
(0.392) 
 
MN total, BN with MN, BN with NPB and BN with NBUD are per 1000 BN 
 
Many significant correlations were found (Table 15), especially with folic acid and vitamin B12. No significant correlations were 
found with UCB. 
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A number of significant correlations were found either in men or women or in 
the whole study population (Table 16). Non-significant correlations are not 
shown. 
 
Table 16. Correlations between different variables in men and women. 
Correlation Men R (pVal) Women R (pVal) 
Age & MN total in BN/1000 BN 0.424 (0.000***) 0.729 (0.000***) 
Age & folic acid -0.522 (0.000***) -0.467 (0.012*) 
MN total in BN/1000 BN & folic acid -0.161 (0.196) -0.497 (0.010**) 
Vitamin B12 & BN with NBUD/1000 BN -0.500 (0.000***) -0.365 (0.061) 
MN total in BN & BN with NBUD/1000 BN 0.397 (0.001***) 0.489 (0.008**) 
 
 
 
 
 
 
 
 
 
 
Learn from yesterday, live for today, hope for tomorrow. 
The important thing is not to stop questioning. 
Albert Einstein 
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5 CONCLUSIONS 
 
In the present work, the effects of unconjugated bilirubin on oxidative DNA 
damage were investigated in peripheral blood lymphocytes of 100 healthy 
individuals. Bilirubin has been reported to have antioxidant properties and could 
therefore protect from oxidative damage. The study population was divided into 
three groups, referring to their determined unconjugated bilirubin 
concentrations, and their DNA damage parameters micronuclei, nucleoplasmic 
bridges and nuclear buds were compared. However, no statistical differences 
were found between the groups. Nevertheless, this study shows first results for 
elevated serum bilirubin levels and the micronucleus assay, and can be 
regarded as a novel finding. The collected data are highly valuable and can be 
an impulse for other researchers. 
We could show that micronuclei were increased with age and that women had 
higher micronuclei frequencies than men. Both findings are in line with the 
literature. The average age of the present study population was 32 years, for 
further investigations we would suggest an older population, as a protecting 
effect of bilirubin might be noticeable by lengthen the exposure time of UCB. 
There was a hint of less DNA damage in older participants with high bilirubin 
concentrations, however, to prove that fact, more studies need to be done. 
Moreover, we could show dietary influences on DNA stability. Folic acid and 
vitamin B12 are involved in DNA metabolism, as deficiencies lead to the 
incorporation of uracil. In our study, especially vitamin B12 was shown to have 
protective properties on DNA stability. Individuals with high concentrations of 
this micronutrient showed significantly less DNA damage than persons with low 
vitamin B12 levels. These vitamins have been earlier reported to be protective. 
As other antioxidants (e.g. vitamin E) have been reported to show a protective 
effect on DNA, measured by the cytokinesis-block micronucleus assay [Fenech 
et al., 2005], it might be possible to find a protective effect of bilirubin. Further 
research needs to be done to get more insights on this strong and potent 
antioxidant. 
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6 SUMMARY 
 
The aim of the present study, a project funded by the FWF-Austrian Science 
Fund (project number P21162), was to investigate the physiological relevance, 
especially the antioxidative and anticancer effect of unconjugated bilirubin in 
humans. 
Therefore, persons with mildly elevated unconjugated bilirubin concentrations, 
diagnosed with Gilbert’s syndrome, as well as healthy individuals as controls, 
were recruited. In total, 100 subjects completed the study and gave blood 
samples. Unconjugated serum bilirubin was determined by HPLC. This 
assessment was the basis for the allocation of the subjects into different groups. 
To measure DNA damage, the cytokinesis-block micronucleus assay was 
conducted, a state of the art method for detecting chromosomal DNA damage in 
humans. Lymphocytes were isolated from the blood samples, treated and fixed 
on slides. Cells were examined under a microscope and scored. In these 
binucleated cells, micronuclei, nucleoplasmic bridges and nuclear buds can 
occur, which are DNA damage markers and indicate chromosomal 
rearrangement. 
Bilirubin has been reported to have antioxidant properties, therefore it was 
hypothesized that individuals with elevated bilirubin concentrations show less 
DNA damage markers than controls. However, the hypothesis could not be 
confirmed, there were no significant differences between the groups, 
concerning bilirubin concentrations. But we could show that micronuclei 
increase with age and that women have more micronuclei than men. This might 
indicate that the study population was too young (average 32 years) to show 
significant differences. Another result of the study was that subjects with high 
vitamin B12 concentrations had less DNA damage, confirming that this vitamin 
is involved in the DNA metabolism. 
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7 ZUSAMMENFASSUNG 
 
Ziel der vorliegenden Arbeit, einem Projekt, das vom Österreichischen 
Wissenschaftsfonds (FWF, Projekt Nummer P21162) unterstützt wird, war, die 
physiologische Bedeutung von unkonjugiertem Bilirubin am Menschen zu 
untersuchen. Besonderes Augenmerk lag dabei auf der antioxidativen und 
antikanzerogenen Wirkung von Bilirubin. 
Zu diesem Zweck wurden Personen mit leicht erhöhtem unkonjugierten 
Serumbilirubin, diagnostiziert mit Gilbert’s Syndrom, und gesunde Probanden 
als Kontrollgruppe, rekrutiert. Insgesamt beendeten 100 Personen die Studie 
und gaben Blutproben ab. Die Serumkonzentration von unkonjugiertem Bilirubin 
wurde mittels HPLC bestimmt. Diese Konzentration war die Grundlage für die 
Zuordnung der Probanden in unterschiedliche Gruppen. Um die DNA Schäden 
zu messen, wurde die Methode des cytokinesis-block micronucleus assay, 
einer Standardmethode zur Messung von chromosomalen DNA Schäden am 
Menschen, angewandt. Dabei wurden Lymphozyten aus dem Blut isoliert, 
behandelt, auf Objektträgern aufgetragen und fixiert. Diese Zellen wurden unter 
dem Mikroskop untersucht und gezählt. In Zweikernzellen können Mikrokerne, 
nukleoplasmatische Brücken und nukleare Buds auftreten, welche auf DNA 
Schäden hinweisen und Biomarker für diese sind.  
Es wurde gezeigt, dass Bilirubin antioxidative Wirkungen hat. Deshalb wurde 
die Hypothese aufgestellt, dass Personen mit leicht erhöhtem Bilirubinspiegel 
geringere DNA Schäden aufweisen, als die Kontrollgruppe. Es konnten jedoch 
keine signifikanten Unterschiede gezeigt werden, die Hypothese konnte also 
nicht bestätigt werden. Es wurde jedoch festgestellt, dass Mikrokerne mit dem 
Alter ansteigen und dass Frauen höhere Mikrokernwerte aufweisen als Männer. 
Dies könnte bedeuten, dass die Studienpopulation zu jung war 
(Durchschnittsalter: 32 Jahre) um signifikante Unterschiede zeigen zu können. 
Eine weitere Beobachtung war, dass Personen mit hohen Vitamin B12 
Konzentrationen weniger DNA Schäden aufwiesen. Dies ist ein Hinweis auf den 
Einfluss dieses Vitamins auf den DNA Metabolismus. 
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